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Abstract 
Early detection of biomarkers of tumour treatment response improves clinical 
management, in vivo. Magnetic resonance spectroscopy (MRS) has demonstrated potential 
for identifying early biomarkers of effective treatment. However, more detailed in vitro 
studies are required to improve our understanding and facilitate its use.  
The aim of this study is to determine 
1
H high-resolution magic angle spinning (HR-MAS) 
nuclear magnetic resonance (NMR) biomarkers of cytostasis and cell death in a rat glioma 
BT4C cell line.  
 
Cytostasis and cell death were induced in BT4C cells using cisplatin and substrate free 
medium, respectively. Cell viability was examined by various techniques. The lipid and 
metabolite alterations in whole cells were investigated by 
1
H HR-MAS NMR.  
 
Significant alterations in lipids and metabolites were detected in response to cytostasis or 
necrosis. NMR lipid accumulation was associated with an increase in cytoplasmic lipid 
droplets seen prior to morphological and molecular markers of cell death. Significant 
differences were detected in individual choline containing metabolites (CCMs), 
emphasising the importance of identifying CCMs separately. Alterations were also 
detected in lactate, alanine, glycine, glutamate, and succinate levels, suggesting changes in 
the energy metabolism pathways which may provide novel biomarkers in vivo. 
 
1
H HR-MAS NMR reveals alterations in lipids and metabolites during cytostasis and cell 
death which may provide early markers of treatment efficacy. 
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Figure 1.1. Schematic image of the magnetic resonance 
spectroscopy (MRS) effect. (A and B). A specific 
radiofrequency causes the nuclei to move to the 
other magnetic state. In absence of 
radiofrequency, the nuclei return to equilibrium. 
The resonant waves are registered and presented 
as peaks. (C). Radiofrequencies are applied during 
MRS and the waves resonate according to the 
nuclei and the surrounding environment.  
 
7 
Figure 1.2. Schematic image of the events occurring in cells 
during apoptosis and necrosis cell death. During 
apoptosis chromatin condenses and cell shrinks 
and membrane blebbing occurs. During the final 
stages, cell breaks up to cluster of apoptotic 
bodies. During necrosis, cell swells and blebbing 
and vacuolisation occur. Cell membrane becomes 
permeable and at final stages cell shrinkage and 
lysis occur.  
 
26 
Figure 1.3. Autophagy pathway and its many functions. 
Autophagy is stimulated by metabolic stress or 
cancer therapies. Autophagosome sequesters 
cytoplasmic material and fuses with lysosome, 
forming an autolysosome. Degradation of 
cytoplasmic material generates free fatty acids and 
amino acids, which can result in energy 
production, protein synthesis, or removal of 
harmful proteins. Autophagy can cause cell death 
by self- cannibalism and/or apoptosis. 
 
31 
Figure 1.4. Cell cycle process and cell check points. Cell 
cycle is controlled by G1, S-phase, and mitotic 
cyclin-dependent kinase complexes (Green). 
Ubiquitin ligase complexes SCF and APC 
polyubiquitinate S phase inhibitors, securing, and 
mitotic cyclins for degradation by proteasomes. 
Proteolysis of these substrates activates the 
relevant cyclin-CDK complexes, leading to cell 
cycle progression. 
 
34 
Figure 1.5. The biochemistry of DNA fragmentation during 
apoptosis and the appearance of 180-200 bp DNA 
37 
xi 
 
fragments as ladder pattern on gel electrophoresis. 
 
Figure 1.6. 
 
Schematic representation of loss of cell membrane 
asymmetry during early stages of apoptosis. PS 
molecules are located in the inner layer of the cell 
membrane (orange circles). During apoptosis they 
are translocated to the outer membrane. FITC 
labelled annexin V has high affinity to the 
exposed PS. 
38 
   
Figure 1.7. Cisplatin interaction with DNA. (a) inter-strand 
cross-link. (b) 1,2-intra-strand cross-link. (c) 1,3-
intra-strand cross-link. (d) protein-DNA cross-link 
 
41 
Figure 2.1. A schematic image of a Neubauer 
haemocytometer slide and the grids used to count 
the cells. 
 
46 
Figure 2.2. A Shandon cytospin. 
 
48 
Figure 2.3. Image of assembled filter card, cytofunnel, and 
cytoclip.   
 
48 
Figure 2.4. A Varian 600 MHz spectrometer at the Henry 
Wellcome Buildining, The University of 
Birmingham. 
53 
Figure 2.5. A typical spectrum of BT4C cells. The TARQUIN 
algorithm was used to identify and quantitate 
metabolite and lipids in the spectrum. The residual 
spectrum is shown at the top section of the image. 
56 
Figure 2.6. Trypan blue staining of BT4C cells. Dead cells 
appear darker and viable cells are identified as 
brighter, unstained cells. Only a few of the dead 
cells are labelled in this image.  
 
58 
Figure 2.7. Haematoxylin and eosin staining of BT4C cells. 
Morphological characteristics of the cell nuclei 
help in identifying necrotic and apoptotic cells. 
Apoptotic cells contain fragmented nuclei and 
necrotic cells have dispersed nucleus.  
 
60 
Figure 2.8. Cell cycle analysis platform of multicycle 
software version 3. A control sample is used to 
define the G1 and G2 ranges. The defined regions 
are used to fit the treated samples and the optimal 
fits are presented as fraction of cells in each phase 
of the cell cycle.  
67 
xii 
 
 
Figure 2.9. ImageJ 1.38X platform for threshold detection. 
The threshold of the lipid droplet and the whole 
cell were selected based on where they were 
identified. The selected areas were then measured 
and the percentage of the cell area covered by 
lipid droplets was calculated.  
 
72 
Figure 2.10. ImageJ 1.38X platform for image measurements. 
The diameter of a lipid droplet is measured by 
drawing a line across the droplet and measuring 
the length of the line.  
 
73 
Figure 3.1 Flow chart of the methods used in chapter 3 and 4. 80 
Figure 3.2. Images of control and cisplatin treated cells after 
various time intervals (12, 24, 48, 72 hrs), stained 
with H&E. The arrows are pointing to apoptotic 
cells and the arrow heads are showing the necrotic 
cells. The scale bars represent 20 micrometer. 
 
83 
Figure 3.3. Percentages of dead cells revealed by H&E (♦) 
and trypan blue (■) staining in untreated and after 
12, 24, 48, or 72 hrs cisplatin exposure in BT4C 
cells.  The error bars are SEM and the significant 
differences are identified by comparing each time 
point with the control, untreated samples (n=3 for 
each time point, *p<0.05, **p<0.001).  
 
84 
Figure 3.4. Percentages of apoptotic and necrotic cells 
revealed by annexin V-FITC flow cytometry. To 
confirm the high percentages of viable cells 
detected by trypan blue and H&E staining after 
12, 24, or 48 hrs cisplatin exposure, cells were 
labelled and stained with annexin V-FITC and PI. 
The cells were then analysed with flow cytometer 
and the data were processed with FlowJo (n=3 for 
each time point). 
 
86 
Figure 3.5. Detecting DNA fragmentation. DNA was 
harvested from untreated and cisplatin treated 
BT4C cells (12, 24, 48, or 72 hrs) according to the 
procedures described in the method section. The 
DNA harvested from the cells was ran on gel 
electrophoresis to determine presence of the 
ladder pattern, a typical late stage marker of 
apoptosis (A. 1: negative control, 2,9: positive 
87 
xiii 
 
control, 3,6: untreated cells, 4,7: 48 hrs cisplatin 
exposed cells, 5,8: 72 hrs cisplatin exposed cells; 
B.1: negative control, 2: positive control, 3,6: 
untreated cells, 4,7: 24 hrs cisplatin exposed cells, 
5,8: 48 hrs cisplatin exposed cells).  
 
Figure 3.6. 
1
H HR-MAS NMR spectra of BT4C cells 
following cisplatin exposure. (A) 0.5 to 4.5 ppm 
region. Metabolites labelled are as follows:  1- 
lactate, 2-alanine, 3- glutamate, 4- succinate, 5- 
glutamine and aspartate, 6- creatine, 7- choline, 8- 
GPC and PC, 9- taurine, 10- scyllo-inositol, 11- 
glycine, 12- myo-inositol, 13- Guanidioacetate.  
90 
Figure 3.7. Choline containing region. Metabolites labelled on 
the control spectrum are as follows: 1- choline, 2- 
phosphocholine, 3- glycerophosphocholine, 4- 
taurine, 5- phosphatidylcholine 6- glycine).
 
91 
Figure 3.8.  PCA of the 19 fitted metabolite quantities of 
cisplatin exposed cells. (A) Scores plot. (B) 
Loadings for principal component 1. (C) Loadings 
for principal 2. 
 
95 
Figure 3.9. 
 
Phospholipid metabolism. The activities of 
phospholipase A2 and lysophospholipase result in 
production of GPC and fatty acids and 
phospholipase C activity results in degradation of 
phosphatidylcholine and production of 
phosphocholine. 
 
99 
Figure 3.10. The metabolite pathways relevant to metabolite 
alterations in cisplatin exposed BT4C cells. 
Damaged DNA may activate poly (ADP-ribose) 
polymerase (PARP), a DNA repair enzyme which 
results in consumption of NAD and inhibition of 
glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH) activity (indicated by a red circle). 
Hence glucose dependent ATP production is 
inhibited. In this diagram the metabolites with red 
arrows altered significantly with longer exposure 
to cisplatin in BT4C cells. 
 
102 
Figure 4.1.1. Nile red and DAPI images of cisplatin exposed 
cells for various times of 12, 24, 48 or 72 hrs. 
Cells were stained with Nile red and DAPI and 
images were captured by a Nikon E600 
microscope coupled to a SPOT RT KE colour 3 
shot CCD camera. Gray scale images were 
113-114 
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acquired and then images were psudocoloured red 
and blue to represent Nile red and DAPI, 
respectively. Coloured Nile red and DAPI images 
were then merged (The scale bars represent 20 
micrometers). 
 
Figure 4.1.2. Representative images of mitotic, viable, apoptotic 
and necrotic cells detected by Nile red and DAPI 
co-staining (The scale bars represent 5 
micrometers). 
 
115 
Figure 4.2. Mean percentage of cell area covered by lipid 
droplets in untreated and cisplatin treated samples 
(12, 24, 48, or 72 hrs) (*p<0.05, **p<0.001; the 
error bars are SEM). 
 
110 
Figure 4.3. Lipid droplet diameter of untreated and cisplatin 
exposed cells (12, 24, 48 or 72 hrs). The results 
are presented as micrometer (µm) (*p<0.05, 
**p<0.001; the error bars are SEM). 
 
117 
Figure 4.4. Percentages of dead cells revealed by DAPI 
staining in untreated and cisplatin exposed 
samples of different time points of 12, 24, 48 or 
72 hrs (the sum of apoptotic and necrotic cells ♦, 
apoptotic ■, and necrotic ▲ cells) (*p<0.05, 
**p<0.001; the error bars represent SEM).   
 
119 
Figure 4.5. TEM images of control and 24 hrs cisplatin 
treated cells (LD- lipid droplets; SM- swollen 
mitochondria; V- vacuoles; IM- intact 
mitochondria). 
 
121 
Figure 4.6. 
1
H HR-MAS NMR spectra of untreated and 
cisplatin exposed cells of various time points of 
12, 24, 48, or 72 hrs (Lipid signals labelled on the 
control spectrum are as follows: 1- 0.89  ppm, 2- 
1.3 ppm, 3- 1.58 ppm, 4- 2.02 ppm, 5- 2.2 ppm, 6- 
2.8 ppm, 7- 5.4 ppm). 
 
122 
Figure 4.7. Ratio of the signals -CH2-CH2-CH2-/-CH3 did not 
alter by longer exposure to cisplatin showing that 
the mean chain length remains unchanged.  
 
125 
Figure 4.8. Phospholipid metabolism. Phospholipase A2 and 
lysophospholipase activity result in production of 
GPC and fatty acids. Fatty acids can be used in 
production of phospholipids and triglycerides. 
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Figure 5.1. Flow chart of the methods used in chapter 5. 139 
Figure 5.2. The percentages of necrotic cells detected by 
different methods of staining, trypan blue (♦), 
H&E (■), and DAPI (▲). The error bars are SEM. 
(*p<0.05, **p<0.001). 
 
141 
Figure 5.3. Images of control and starved cells after various 
time intervals (4, 6, 12, 18, or 24 hrs), stained with 
H&E. The arrows are pointing to necrotic cells 
and the scale bars represent 20 micrometers. 
 
142 
Figure 5.4. Nile red and DAPI images of starved cells. 
Control and starved cells for various times of 4, 6, 
12, 18 or 24 hrs were stained with Nile red and 
DAPI. A Nikon E600 microscope coupled to a 
SPOT RT KE colour 3 shot CCD camera was used 
to visualise and capture gray scale images. The 
images were merged after they were 
psudocoloured red and blue to represent Nile red 
and DAPI, respectively (The scale bars represent 
20 micrometer). 
 
144-145 
Figure 5.5. The mean percentages of cell area covered by 
lipid droplets in starved cells. The error bars are 
SEM (*p<0.05). 
 
147 
Figure 5.6. The diameter of cytoplasmic lipid droplets of 
starved cells. The error bars are SEM (*p<0.05, 
**p<0.001). 
 
148 
Figure 5.7. TEM images of control and starved cells after 6, 
12, and 24 hrs (LD- lipid droplets; A- autophagic 
bodies; SM- swollen mitochondria; M- myelinoid 
bodies; V- vacuoles; IM- intact mitochondria). 
 
150 
Figure 5.8. 
1
H HR-MAS NMR spectra of BT4C cells 
following substrate starvation. (A) 0.5 to 4.5 ppm 
region. Metabolites labelled are as follows:  1- 
lactate, 2-alanine, 3- glutamate, 4- succinate, 5- 
glutamine and aspartate, 6- creatine, 7- choline, 8- 
GPC and PC, 9- taurine, 10- scyllo-inositol, 11- 
glycine, 12- myo-inositol, 13- guanidioacetate.  
 
152 
Figure 5.9. 
1
H HR-MAS NMR spectra of BT4C cells 
following substrate starvation. (A) 0.5 to 4.5 ppm 
region. (B) Choline containing region (metabolites 
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labelled on the control spectrum are 
as follows: 1- choline, 2- phosphocholine, 3- 
glycerophosphocholine, 4- taurine, 5- 
phosphatidylcholine 6- glycine). 
 
Figure 5.10. PCA of 
1
H HR-MAS NMR metabolite profiles for 
substrate starved cells. (A) Scores plot, (B) 
Loadings for principal component 1, (C) Loadings 
for principal component 2.  
 
161 
Figure 5.11. PCA of 
1
H HR-MAS NMR metabolite profiles for 
cisplatin exposed and substrate starved cells (A) 
scores plot, (B) loadings for principal component 
1, (C) loadings for principal component 2. 
 
163 
Figure 5.12. The relevant metabolite pathways in starved 
BT4C cells. In this diagram, the metabolites with 
red arrows altered significantly with longer 
substrate deprivation. 
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1.1. Introduction 
Early detection of tumour response to therapy influences tumour management and affects 
the outcome of the therapy. It allows for identification of unsuccessful strategies and 
application of alternative treatments. This would also prevent the patients from 
experiencing toxic side effects of unsuccessful chemotherapeutic drugs (1).  
Examining the tumour size by conventional imaging techniques and histopathological 
examination of biopsy samples are the standard approaches to monitoring tumour 
treatment response. However, alterations in tumour size detected by conventional imaging 
techniques such as magnetic resonance imaging (MRI) usually occur weeks or months 
after the treatment is initiated. Histopathological examination is only reliable if the whole 
tumour can be removed and is unsatisfactory in particular for heterogeneous tumours that 
are difficult to resect completely such as glioma (2). This approach is invasive and is rarely 
used for tumours in regions which are not easily accessible such as the central nervous 
system (CNS). It also suffers from the disadvantage that it is difficult to repeat at different 
times during treatment.  
A non-invasive and accurate technique for determining tumour response would greatly aid 
the management of many tumour types. Magnetic resonance spectroscopy (MRS) is a 
promising technique that can be used for early detection of tumour response to treatment 
by providing information on the metabolite profile of the tumours and their alterations in 
response to therapy.  
MRS is one of several methods used to determine metabolite profiles. Metabolomics is the 
study of the complete set of metabolites of biological systems such as cells, tissues, or 
organisms which alter in response to physiological, developmental, or pathological status 
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(3, 4). As most of the metabolites are conserved, the results can be compared across 
species, making metabolomics a particularly useful approach amongst „–omic‟ techniques 
(3).  
In tumour studies, metabolomics has been used to understand better the pathogenic 
mechanisms by monitoring tumour growth, progression, regression and occurrence of 
events such as apoptosis (3). It has also been employed to monitor tumour treatment 
regimes and to identify new targets for anti-cancer drugs.  
Various metabolomic analysis methods are available in vitro: nuclear magnetic resonance 
(NMR) spectroscopy (MRS in clinical settings), gas chromatography- and liquid 
chromatography- mass spectrometry (GC-MS and LC-MS), thin-layer chromatography 
(TLC), metabolite arrays, and Fourier–transform infrared (FT-IR) spectroscopy. These 
instruments are fully automated and after purchase, analysing samples is relatively cheap 
(3). 
MS and NMR spectroscopy are the most common techniques used. MS is more sensitive 
than NMR (3). However, MS sample preparation is time consuming and some metabolites 
are poorly ionised. NMR is a non-invasive, reproducible and quantitative technique with 
the advantage that it can be used in vivo. Increased reliability and automation together with 
decreased acquisition times have increased the applicability of this method in the clinical 
setting and in particular as a complement to MRI.  
Most of the tumour metabolomic research has involved MRS based studies. Some 
researchers have focused on identifying MRS metabolite alterations in response to tumour 
treatment and assigning them as biomarkers of effective tumour therapy (3). Clinical 
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management of certain tumour groups such as glioma may particularly benefit from MRS 
studies. 
Glioma is the most common form of primary brain tumour (5). With a heterogeneous and 
highly invasive nature, the results of standard methods of diagnosing and treatment 
monitoring are often poor (2, 6). As the results influence the chosen treatment and the 
outcome of the therapy, MRS may improve the success of glioma treatment by identifying 
early markers of effective treatment. However, despite the increasing use of MRS in the 
clinical setting, there is still relatively little understanding of the metabolite changes 
detected and in vitro studies are required to improve this understanding. Rat glioma BT4C 
cells are a useful in vitro model to investigate the potential of MRS in detecting early 
markers of glioma response to treatment. 
The majority of anti-cancer drugs induce apoptosis and some induce cytostasis in tumour 
cells (7, 8). However, as tumour cells develop resistance to apoptosis, application of 
necrosis-inducing treatments has been considered (9). Majority of studies have focused on 
MRS lipid and metabolite alterations in response to apoptosis (section 1.7) and although, 
1
H MRS offers the potential to detect simultaneously a wide range of metabolites, in most 
previous studies small numbers of metabolites have been identified and examined.  
MRS investigations of metabolite alterations in response to cytostasis prior to apoptosis 
may provide early markers of cell death and examining the metabolite profile of cells 
during necrosis may result in identification of specific markers of necrosis and/or may 
provide further information on the general markers of cell death. In addition studying the 
altered metabolite profiles may lead to better understanding of the effected pathways. 
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1.2. Aim of This Thesis 
To identify general biomarkers of cell stress and specific markers of cytostasis and cell 
death in rat glioma BT4C cells  by  
1
H high resolution (HR) magic angle spinning (MAS) 
NMR spectroscopy.  
 
1.3. Basic Principles of Magnetic Resonance Spectroscopy 
MRS is a non-invasive technique (2, 10) which can be used in vivo and in vitro. Therefore, 
the findings from cellular and animal models are potentially transferable to clinical settings 
(7) making it attractive to both biologists and clinicians. MRS is closely related to 
magnetic resonance imaging but MR spectroscopy provides information on low molecular 
weight metabolites (11, 12), mobile fatty acids (11), and polypeptides (13) rather than 
anatomical structure. MRS is a term used for in vivo studies and originates from the use of 
this technique in a clinical setting and the term NMR spectroscopy is used when MRS is 
applied in vitro. 
MRS is based on the principle that a number of atomic nuclei have intrinsic magnetic 
properties when placed in magnetic fields and are able to align with the applied field. The 
magnetic property of some isotypes causes the nuclei to act as a small magnetic bar. In a 
magnetic field the magnets align (known as spinup) or oppose (Know as spindown) to the 
external field. Spinup is slightly favoured over spindown state. Nuclear spins can move 
between the two states by using radiation at the right frequency. The applied 
radiofrequency causes the nuclei to flip in to the other magnetic state (figure 1.1). After the 
radiofrequency, the system returns to equilibrium. The difference between the populations 
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of the two magnetic energy states is detected as radiowaves during the return of the nuclei 
to the start point (3). The radio waves resonate at specific frequencies determined by the 
atomic nuclei and their electronic environment (figure 1.1).  
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Figure 1.1. Schematic image of the magnetic resonance spectroscopy (MRS) effect. (A 
and B). A specific radiofrequency causes the nuclei to move to the other magnetic state. In 
absence of radiofrequency, the nuclei return to equilibrium. The resonant waves are 
registered and presented as peaks. (C). Radiofrequencies are applied during MRS and the 
waves resonate according to the nuclei and the surrounding environment.  
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The frequencies at which the radiation resonates, are detected and registered (10). The 
measured signals are then presented as peaks on a normalised frequency scale. The 
position of the peaks depends on the resonant frequencies of the related metabolite (14). 
The result is a spectral pattern of the chemical compounds. Each metabolite and 
component produces signals at different frequencies and frequencies are very much 
sensitive to the position of the atomic nuclei in the molecule and the surrounding 
environment of the nuclei (2, 10). The metabolite profile of the sample can be determined 
from these MR spectral patterns. The areas under the peaks are determined by the 
concentration of the metabolites and if the concentration of a reference metabolite is 
known (14) the relative concentration of the other metabolites can be calculated (2).  
Therefore MRS is a quantitative method as well as a qualitative technique (15). 
Any nucleus with non zero spin can be studied by MRS, however only hydrogen (
1
H), 
phosphorous (
31
P) and carbon (
13
C) are commonly studied (15). Signals arising from 
1
H or 
31
P atoms of endogenous metabolites and 
19
F signals of anticancer drugs are the focus of 
clinical MRS of cancer. In addition 
13
C and 
2
H are used to investigate exogenously 
administered substances (2). Protons have a relatively large magnetic moment. Therefore, 
1
H MRS is a sensitive method, allowing small volumes to be examined (16). As protons 
are present in nearly all compounds (2), a large number of intracellular compounds such as 
small metabolites, phospholipids and polypeptides (17) are detectable; therefore 
1
H MRS 
contains wealth of information (2) and has been the most used and interesting MRS 
technique (10) for metabolite studies in biological systems in vivo and in vitro (17). 
MRS can be fully automated and has a high degree of reproducibility in analysis of 
biofluid. The current detection limit using 
1
H NMR for tissue extracts and or biofluids is of 
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the order of 100 µM. It is relatively easy to determine metabolites from simple one-
dimensional spectra (3). 
Although a monolayer culture does not represent characteristics of a three dimensional 
tumour, cell lines are useful models for studying NMR markers of therapy response. They 
are commercially available and by using the same culture conditions similar samples are 
achieved and assays can be repeated. Using tissue samples and animal models require 
ethical approval. The samples are limited and tumours are usually contaminated with 
normal cells. In addition studies are influenced by surrounding tissues and the micro-
environment. Furthermore NMR spectroscopy on cell samples can be carried out at high 
fields (18), yielding a greater number of metabolites (19). 
In this work 
1
H HR-MAS NMR is used. Due to restricted motion and high magnetic 
susceptibility, NMR spectroscopy analysis of tissue or cells at high magnetic field results 
in broad and overlapping signals. In 
1
H HR-MAS NMR a radiofrequency pulse at a 
specific angle of 54.7º is applied. Use of this angle reduces the effects of dipolar coupling, 
chemical shift anisotropy, and magnetic susceptibility differences. Therefore, spectroscopy 
of inhomogeneous samples such as cells or tissues results in high resolution data.  
HR-MAS is an alternative technique to extraction methods. During extraction methods 
lipids and/or metabolites are removed from cells or tissues. Due to extraction of proteins 
during these procedures, the alteration of the metabolites and lipids are less likely. The 
samples are stable and low temperatures are not needed. In contrast to extraction studies, 
HR-MAS requires minimal preparations (3) on a small amount of samples. This technique 
allows investigation of cells and tissues that are better representative of in vivo models. Via 
HR-MAS high resolution data from inhomogeneous samples can be achieved and as this 
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technique is non-destructive, the cells or tissue sections can be further used for other assays 
such as viability tests. This technique has been used previously for detecting tumour 
response to treatment (20, 21). 
 
1.4. Magnetic Resonance Spectroscopy of Tumours 
MRS is used to determine metabolite profiles of tumours which may be interpreted in the 
context of metabolic pathways in cells, tissues, or organisms. The detected changes reflect 
alterations occurring in tumours such as cell membrane proliferation or degradation, and 
changes in energy metabolism (14) and provides information on processes occurring 
during growth and death (22). The biochemical information obtained facilitates the better 
understanding of physiological and biochemical characteristics of tumours (2).  
Metabolite profiling of tumours can facilitate tumour grading (2, 23), classification (24, 
25) and malignancy determination (26). By identifying type and grade of tumours, MRS 
may contribute to non-invasive diagnosis. Comparison and quantification of metabolite 
profiles of healthy and diseased tissue (2) provides information on the contribution of 
metabolites to the development of healthy or pathological status (17). A large number of 
studies have been carried out to determine the characteristics of brain tumours by 
comparing normal and brain tumour tissues (16, 27, 28). Since 1980 metabolic profiles of 
brain tumours have been studied by MRS (29). The attraction of MRS for brain tumour 
investigation is that the brain has little motion and contains small amounts of mobile lipids 
(2), eliminating the problem of lipid interference with MRS ability to detect other 
11 
 
metabolites (28). MRI is also a standard investigation for patients with brain tumours 
allowing simple incorporation of MRS in clinical protocols. 
Clinical management and therapy planning is founded on correct diagnosis based on 
tumour type and grade of malignancy. The current gold standard for identifying cancer 
type and the degree of malignancy is biopsy  and histopathological examination of the 
samples (30). As the degree of malignancy can vary in the same lesion, histopathology of a 
small biopsy sample may not represent characteristics of the whole tumour mass (31). 
Therefore to reliably determine the degree of malignancy, gross resection or multiple 
biopsies are required (32).  With 1.7% mortality rate associated with biopsy procedures 
(30), a non-invasive technique such as MRS is a promising tool for guiding biopsy and 
making a non-invasive diagnosis in regions that are difficult to biopsy within the CNS 
(33).  
 
1.5. Role of MRS in Monitoring Treatment Response 
Although non-invasive diagnosis is an important goal, a potentially more important role for 
MRS is in treatment monitoring and this is the focus of our attention. The traditional and 
current methods of detecting tumour therapy response are based on detecting a decrease in 
tumour size radiographically, by MRI, computed tomography (CT) or ultrasound. After a 
few months of therapy, changes in tumour volume are detectable with effective treatment. 
As it is not possible to collect information radiographically on the tumour response to 
therapy at early stages of treatment, patients might undergo a course of toxic therapy for 
weeks or months before it is realised that the treatment is not successful. Furthermore, 
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early detection of tumour response to therapy is a powerful determinant of long term 
treatment outcome for aggressive tumours (34). Therefore, there is a need for early 
predictors of tumour response to therapy. 
1
H MRS offers an alternative to tumour size for 
evaluating tumour response and identifying early predictors of successful treatment. MRS, 
by detecting and measuring tumour metabolites at early stages and during the course of 
treatment, has the potential to evaluate tumour response.  
MRS can be used to compliment MRI in clinical settings. MRI is useful for determining 
anatomical localisation of intracranial tumours and to determine the extent of tumour mass 
for surgery and radiotherapy planning (31) and MRS by providing additional information 
on tumour metabolism can supplement the morphological data obtained from MRI. The 
aim is to use MRS and MRI in clinical settings and in some circumstances as a 
replacement for currently applied invasive diagnosis and monitoring methods. The 
combined application of imaging and spectroscopy in evaluating brain tumours has 
reached a stage that enables their use in a clinical environment in diagnosis, therapy 
planning and treatment follow-up (35, 36) but a more detailed understanding of metabolite 
profiles and their changes with treatment is required to inform these clinical studies. 
 
1.6. Treatment induced MRS alterations 
As discussed, detecting early biomarkers of tumour response to treatment is beneficial in 
predicting long term tumour outcome (34) and provides the opportunity to detect 
unsuccessful treatment early on. Assessment of tumours before and during treatment 
provides the opportunity to determine the pathophysiological changes occurring in 
response to treatment and the detected alterations in tumour metabolism by MRS may be 
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useful as predictors of treatment response early on and prior to detection of decrease in 
tumour size (7). 
A number of studies have investigated alterations in lipids and low molecular weight 
metabolites in different tumours in response to various treatment methods. In the following 
sections a number of MRS studies identifying lipid and low molecular weight metabolite 
alterations in response to treatment are described. 
 
1.6.1. MRS Lipid Alterations 
In the past 10-15 years the phenomenon of NMR-visible lipids in cancer tissues has been 
the centre of interest (8). Mobile fatty acyl chains of triglycerides (TGs), free fatty acids 
and cholesteryl esters (22) give rise to well resolved signals in 
1
H NMR spectra of 
malignant cells (37, 38). There has been some controversy over the location of the fatty 
acyl chains. Using labelled radioisotopes and/or isolated membranes some studies suggest 
that NMR visible lipids arise from fatty acyl chains located in the membrane associated 
microdomains (39, 40). 
Others provided increasing evidence that the cytoplasmic lipid droplets are the source of 
the detected lipids. The evidence was provided based on molecular diffusion experiments 
(41, 42), line width measurements of the lipid signals under different temperatures and 
spinning rates (21), light and/or fluorescent microscopy examination of samples stained 
with dyes such as Nile red (43-46), Oil red O (46-48) and/or electron microscopy studies of 
ultrathin sections or subcellular fractions (42, 44, 47, 49, 50).  
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Using radioisotope labelling and isolated membrane ghosts Mountford et al. associated the 
increases in lipid resonances detected in 
1
H NMR spectra of transformed cultured 
lymphocytes with lipid bilayers (40) which were in or attached to the cell membrane (37). 
They suggested the detected changes in human lymphoblastoid cell lines are indicative of 
type of transformation and stage of differentiation (51) and the detected increase in lipids is 
due to an increase in cell membrane fluidity caused by cell stimulation or transformation 
(40).  
May et al. assigned the lipid resonances to the neutral lipids in the plasma membrane; with 
TGs as the main element (52). They were then shown to have similarities with very low 
density human lipoproteins, rich in TGs (Chylomicra and very low density lipoproteins 
(VLDL)) by Williams et al. (53).  
Blankenberg and colleagues detected an increase in the methylene (CH2) resonance at 1.3 
ppm in apoptotic Jurkat T-cell lymphoblast cultures induced by doxorubicin, 
glucocorticoids or serum deprivation. In addition, a similar increase in the methylene 
signal of apoptotic Daudi (B-cell) Burkitt‟s lymphoma cell cultures and JY T-cell ALL 
lines treated with doxorubicin was detected by this group (54). It was suggested that lipid 
resonances are rarely visible in viable, intact lymphocytes due to immobility of acyl chains 
in the lipid plasma membrane (54). Therefore, a decrease in microviscosity of the cell 
membrane along with other factors such as loss of cytoskeletal architecture were suggested 
to result in increase mobility and NMR visibility of lipid membrane during induction of 
apoptosis via various stimuli and within different cell lines (54). Down regulation of 
aminophospholipid translocase and increased activity of phospholipid scramblase during 
apoptosis were also suggested as the reasons behind increase in the cell membrane fluidity 
(55). The ratio of CH2/CH3 was proposed as a means of estimating the proportion of 
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apoptosis in cultures (55). This group did not detect any changes in the lipid pattern of 
Jurket T-cells undergoing necrosis caused by freezing (54).  
In 1994, Kuesel et al. also associated an increase in the lipid signal at 1.3 ppm in human 
grade IV astrocytoma tissues with necrosis. The origin of these lipids was not determined 
(56). In an in vivo study by Remy and his colleagues on an experimental model of rat 
intracerebral glioma, increases in NMR visible lipids were associated with necrosis and the 
origin of these lipids were identified as storage compartments of fatty acids, mainly TGs in 
the form of extracellular lipid droplets (42). 
 Early on in 1993 the work carried out by Callies et al. on a myeloma cell line, suggested 
that cytoplasmic lipid droplets contribute to the appearance of lipid resonances detected in 
1
H NMR spectra (49). The lipid alterations detected in in vivo 
1
H MRS patterns of necrotic 
C6 rat brain glioma were found to be associated with the lipid droplets within the cells 
(46). The same results were found by Barba et al., in stimulated C6 rat glioma cells or in 
cells at saturation density and in a quiescent phase. They proposed that lipid increases can 
be used to determine the proliferation status of the cells (43).  
An increase in 
1
H NMR lipid resonances was detected during apoptosis induced by 
cationic lipophilic phosphonium salts in human breast cell line HBL-100. The source of 
lipids was associated with an increase in lipid droplets (47). Di Vito et al. identified an 
increase in lipid patterns in both apoptotic and non-apoptotic, activated T-lymphoblastoid 
cells. Proposing lipid droplets as the source of the detected lipid increase, they also 
suggested a possible similarity between the mechanisms behind the rise in lipid intensity in 
both conditions (44). Feretti et al., by studying NIH-3T3 fibroblast cells and their H-ras 
transformants (3T3
ras
) using electron microscopy, suggested contributions from both 
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cytosolic lipid droplets and membrane vesicles to the detected lipid increase in NIH- 3T3 
fibroblasts (45).  
Previous ex vivo and in vivo studies by Hakumaki et al. and Griffin et al. on rat BT4C 
glioma showed increases in MRS detectable lipids including polyunsaturated fatty acid 
lipids (PUFA) after apoptosis induction by Ganciclovir-Thymidine Kinase (GCV) gene 
therapy. They identified lipid droplets as the source of mobile lipids (21, 50). 
During treatment different populations of apoptotic, necrotic, cell cycle arrested and even 
viable cells are detected. Although studies have associated the cytoplasmic lipid droplet 
alterations with the induction of apoptosis, necrosis or cell growth arrest, there has been 
little attempt to quantitatively determine alterations in the lipid droplets in each of the 
different cell populations.  
 
1.6.2. Low Molecular Weight Metabolite Alterations 
As is demonstrated in the following sections large numbers of studies have been carried 
out to identify alterations in non-lipid metabolites and to assess their potential as early or 
surrogate markers of treatment response. 
 
1.6.2.1. Choline Containing Metabolites  
Much of the interest in 
1
H MRS has focused on choline containing metabolites (CCMs). 
Recent in vivo (57, 58) and in vitro (59) studies on human breast tumours and in vivo 
studies of murine radiation-induced fibrosarcoma (RIF-1) showed a decrease in CCMs in 
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response to treatment. Suggesting the potential of CCMs as biomarkers of treatment 
efficacy in breast (58) and RIF-1 tumours (60). 
However, in vivo studies by Lehtimaki et al. on rat glioma models have shown a decrease 
in CCMs only in advanced stages of cell death when tumour cell density has reduced (61). 
Further in vivo and in vitro studies on rat glioma models by Valonen et al. and Griffin et al. 
failed to show any changes in CCMs in response to gene therapy induced apoptosis (20, 
62).  
One explanation for this discrepancy may lie in the relative alterations of the individual 
CCMs since the 
1
H chemical shift dispersion of these metabolites is so small that they 
cannot be discriminated using in vivo 
1
H MRS. Evidence for this explanation comes from 
patterns of individual metabolites contributing to CCM signal identified in in vitro glioma 
studies. Valonen et al. showed increases in glycerophosphocholine (GPC) and 
phosphocholine (PC) levels at early stages of therapy induced apoptosis (62). In contrast, 
Hakumaki et al. identified a temporary decrease in PC and GPC levels at later stages of 
treatment (50). A decrease in the level of PC (20) and an increase in GPC (61) were also 
identified by other researchers. A decrease in tissue PC levels is frequently detected in 
reaction to chemotherapeutic agents (8) and has been suggested to serve as an early marker 
of effective tumour therapy in vivo (63). This further emphasises the potential of individual 
CCMs as markers of treatment and the importance of monitoring each of them separately.  
PC and GPC can be detected individually using 
31
P MRS in vivo and this technique also 
allows the detection of other phosphorylated metabolites such as CDP-choline (64, 65). 
However 
31
P MRS signals arising from these metabolites in vivo are weak and the method 
is not yet widely available clinically. 
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1.6.2.2. Glycolytic Metabolites 
Alterations in glycolytic metabolites have been examined previously. In vivo and in vitro 
31
P MRS analysis of Friend erythroleukemia cells (FLC) and murine fibrosarcoma cells 
treated with tumour necrosis factor (TNF) revealed an increase in glycerol-3-phosphate 
levels (66). In vitro 
31
P NMR studies (cells and extracts) of Chinese hamster ovary cells 
and promyelocytic leukemia cells (HL-60) treated with various drugs also revealed 
increases in glycolysis intermediates. Activation of poly (ADP-ribose) polymerase (PARP) 
enzyme due to damage DNA was suggested as a possible reason for the detected 
alterations (65).  Activity of PARP was also proposed by Ronen et al. as the underlying 
mechanism of the detected 
31
P NMR increase in glycolytic intermediates of doxorubicin 
treated colorectal tumour cells and mechlorethomin treated leukemia cells (L1210) (extract 
studies). They associated the identified alterations with apoptosis and suggested the 
potential of glycolytic intermediates as possible markers of cell death in vivo (67). 
Alterations in lactate, a final product of glycolysis, have been examined previously. The in 
vivo 
1
H MRS levels of lactate in murine RIF-1 tumours remained constant after induction 
of necrosis by vascular disrupting agents (60). 
1
H NMR studies by Chung et al. on extracts 
of human colon tumours after induction of necrosis by histone deacetylase inhibitors 
showed a decrease in glucose levels (68).  
However, 
1
H NMR lactate levels increased in IFN-γ/ TNF-α induced apoptosis in human 
colon carcinoma cells (69) and in TNF treated Friend erythroleukemia and murine 
fibrosarcoma (HeN4) cell extracts (66). In addition a decrease in lactate levels was 
identified in in vivo and in vitro 
1
H MRS examination of murin RIF-1 treated with 5-
fluorouracil. The detected alterations were correlated with increased apoptotic regions in 
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the tumour after treatment (70). The same lactate alteration was detected in in vivo and in 
vitro 
1
H MRS examination of these cells treated with apoptosis inducing 
cyclophosphamide (71). Decreased glucose uptake and glycolytic rate have been suggested 
as the reasons for the identified alterations (70, 72) and lactate has been recommended to 
have potential as a non-invasive marker of tumour treatment response (69-71). 
 
1.6.2.3. Other Low Molecular Weight Metabolites 
1
H MRS can measure a number of other small molecular weight metabolites. Metabolite 
alterations of rat glioma in response to apoptosis induced by ganciclovir treatment have 
previously been investigated (61, 62). Lehtimaki et al. detected a decrease in myo-inositol, 
taurine, glycine, and creatine in vivo. However, they detected increased myo-inositol levels 
and constant taurine levels using in vitro 
1
H NMR (61). Taurine levels investigated by 
Valonen et al. remained constant at early stages of apoptosis and reduced with loss of cell 
density at later stages. In addition, in vitro changes were not detected in the myo-inositol 
levels of glioma (62). More recently, a preliminary study of children with low grade brain 
tumours found myo-inositol to be useful in monitoring treatment (73). 
A reduction in taurine levels has been associated with necrosis induced by vascular 
disrupting agent in in vitro 
1
H NMR studies of murine RIF-1 tumours (60). Also elevated 
levels of taurine have been noted to be associated with levels of apoptosis in untreated 
glioma biopsies (74).  
Alterations in other low molecular weight metabolites were also detected in previous 
studies. A decrease in glutamine and glutamate levels and an increase in a number of 
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amino acids such as valine, leucine, and iso-leucine were detected in human colon 
carcinoma cells treated with histone deacetylase inhibitors (68).  
 
The various profiles detected further emphasises that MRS metabolite profiles of different 
tumours may not be similar in response to treatment and although some metabolite changes 
may be common and be used as general markers, others may alter depending on the tumour 
type, the method of treatment and the nature of induced cell death. 
 
1.7. MRS alterations associated with Cell Death 
A number of studies detected elevated levels of NMR lipids in drug induced cell death 
models (44, 47, 48, 50, 54). As the main pathway of cell death initiated by the majority of 
anti-cancer agents (7, 8) and radiation therapy is apoptosis (75, 76), increasing numbers of 
studies have investigated lipid alterations in tumours after apoptosis induction and an 
increase in mobile lipids has been associated with this type of cell death (44, 48, 50, 54, 
77).  
Others have associated the detected changes in lipids to necrosis in tumours (42, 46, 47, 
56) and some detected an increase in mobile lipids early on during treatment and prior to 
initiation of apoptosis (48, 50, 78, 79). The potential of lipid accumulation as a marker of 
cell cycle arrest and early indicator of tumour response has been demonstrated previously 
(50).   
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The potential of metabolites as markers of therapy induced cell death were also 
investigated in previous studies. Reduced levels CCMs in RIF-1 tumours treated with a 
vascular disrupting agent has been associated with necrosis and cell death (60). Although 
changes in CCMs have been associated with widespread cell death there have been several 
studies which have linked the metabolite changes with earlier events in tumour related 
treatment response.  
Apoptosis induced by various drugs was associated with changes in PC and 
phosphoethanolamine (PEth) in hamster ovary and human promyelocytic leukemia cell 
lines (64). There have also been a small number of studies associating changes in CCMs 
with cell cycle arrest. Decreased levels of PC were detected in treated BT4C glioma cells 
(50, 79) and correlated to the number of cells arrested in G2/M phase of the cell cycle (50). 
Reduced levels of PC were also detected in TNF-α treated breast cancer cells arrested in 
G0/G1+S phase of the cell cycle, prior to apoptosis initiation (80). An increase in total 
choline (tCho) and GPC levels were also identified in growth arrested human prostate 
carcinoma (48). However, the relationship of these metabolite changes to cell death and 
cell cycle arrest has not been well established and some studies have associated them with 
loss of cell density (61, 62). 
Glycolytic intermediates have also been suggested as potential indictors of cell death (64, 
67). Elevated levels of fructose-1,6-bisphosphate along with CDP-choline has been 
suggested as a potential apoptotic marker (64). Lactate levels independently (70, 71) or in 
association with NTP levels (69) have been proposed as markers of effective treatment. 
Based on the association of taurine level with apoptosis in gliomas, Opstad et al. suggested 
that taurine measurements could be useful for in vivo monitoring of apoptosis in glioma 
(74).  
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1.8. Features of Cell Death  
Based on circumstances of occurrence and morphological or biochemical characteristics 
(81), cell death can be classified into three main types: apoptosis, necrosis, and autophagy 
(table 1.1). In organisms homeostasis is sustained by a balance between cell proliferation, 
differentiation and cell death mainly by apoptosis. Impaired apoptotic pathways may lead 
to cancer development amongst many other diseases (64). Although apoptosis plays an 
important role in tumourgenesis, other types of cell death also implicate tumour 
development. 
 
 
 
 
 
 
 
 
 
 
23 
 
Type of cell 
death 
Nucleus 
changes 
Cell 
membrane 
alterations 
Cytoplasm 
changes 
Biochemical 
features 
Common detection 
methods 
Apoptosis 
Chromatin 
condensation; 
nuclear 
fragmentation; 
DNA laddering 
Blebbing 
Fragmentation 
and formation 
of apoptotic 
bodies 
Caspase- 
dependent 
Electron microscopy; 
TUNEL staining; 
annexin staining; 
caspase-activity assays; 
DNA fragmentation 
assay; detection of 
changes in mitochondrial 
membrane potential 
Necrosis 
Clumping and 
random 
degradation of 
nuclear DNA 
Swelling; 
rupture 
Increased 
vascuolation; 
organelle 
degradation; 
mitochondrial 
swelling 
- 
Electron microscopy; 
nuclear staining; 
detection of 
inflammation and 
damage in surrounding 
tissues 
Autophagy 
Partial 
chromatin 
condensation; 
no DNA 
laddering 
Blebbing 
Increased 
number of 
autophagic 
vesicles 
Caspase- 
independent; 
increased 
lysosomal 
activity 
Electron microscopy; 
protein- degradation 
assays; assays for 
marker-protein 
translocation to 
autophagic membranes; 
Monodansylcadaverine 
(MDC) staining 
 
Table 1.1. Morphological and biological features of apoptosis, necrosis, and autophagy 
and their common methods of detection (82). 
 
 
An acute inflammation occurring during tumour cell necrosis may stimulate inflammatory 
response against malignant cells. However, it has been suggested a sustained inflammatory 
response (chronic) can promote tumourgenesis. Further studies are required to identify the 
role of necrosis in tumour development. Although the contribution of autophagy to tumour 
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development is not well understood, it may prevent transformation of normal cells to 
malignant cells by degrading proteins that promote tumourgenesis or by reducing cell 
stress. After a certain threshold, autophagy may promote tumourgenesis by protecting 
malignant cells against stressful conditions (83). 
Chemotherapeutic or hormonal tumour treatment results in apoptosis induction (84). 
However, anti-cancer therapies also induce non-apoptotic cell death and as tumour cells 
develop resistance to apoptosis, treatment methods inducing other methods of cell death 
are being investigated. 
In this work NMR markers of treatment efficacy is investigated and associated with cell 
stress and cell death using various morphological and molecular methods. Therefore, the 
following sections describe various cell death pathways and explain the different methods 
of detection used.  
In addition, as some drugs such as cisplatin induce growth arrest prior to apoptosis, the 
different phases of cell cycle and the importance of the cell cycle check points are also 
discussed. Cell cycle checkpoints ensure proliferation of intact chromatin and detect 
damages to the double strand DNA. This results in cell cycle arrest and initiation of the 
repair systems. However, unsuccessful repair of the damaged DNA may trigger cell death.  
 
1.8.1. Necrosis 
Necrosis was previously considered as an unregulated process (85). However, recent 
evidence suggests that this method of cell death is regulated and consists of serial steps 
(86, 87). Research is ongoing to improve the understanding of the genetic and biochemical 
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pathways involved in necrosis (86). It is initiated in response to cell injury, stress stimuli, 
and activation of ion channels (85, 86). Combined with apoptosis, it has a major role in 
tissue renewal, embryogenesis and immune response. For example, in small intestine, 
apoptosis and necrosis are involved in renewal of entrocytes (87). In situations where 
apoptosis is blocked, necrosis is stimulated (85). 
Necrosis occurs in a number of neighbouring cells and leads to distortion and degradation 
of organelles, followed by cell swelling and rupture (85, 88). Due to cell rupture and 
release of intracellular components, an inflammatory response is activated. Inflammation 
activates immune response, resulting in repair or elimination of damaged or infected tissue 
(85). 
During the initial stages of necrosis chromatin is compact. This stage is known as 
pyknosis. This progresses to clumping of nuclear chromatin on the membrane of the 
nucleus. Mitochondria may become flocculent and sometimes granular matrix is apparent. 
This is followed by swelling of the mitochondrial matrix and rupture of the nucleus, 
organelles, and plasma membrane. The chromatin masses may initially be dispersed and be 
observed as small discrete masses (karyorrhexis) but they will disappear. Cell rupture leads 
to inflammation in adjacent viable tissues and the debris are engulfed by phagocytic cells 
(81) (figure 1.2.). 
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Figure 1.2. Schematic image of the events occurring in cells during apoptosis and necrosis 
cell death (89). During apoptosis, chromatin condenses and the cell shrinks and membrane 
blebbing occurs. During the final stages, the cell breaks up into a cluster of apoptotic 
bodies. During necrosis, the cell swells and blebbing and vacuolisation occurs. The cell 
membrane becomes permeable and at the final stages, cell shrinkage and lysis occur 
 
1.8.2. Apoptosis  
Based on morphological characteristics, apoptosis was originally known as shrinkage 
necrosis (90). High occurrence and importance of apoptosis in healthy and diseased 
organisms, and further morphological studies led to better understanding of this 
phenomenon and therefore it was described and re-named as apoptosis (Greek, meaning 
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apo “off”; ptosis, “falling”) by Kerr et al. in 1972 (88). Apoptosis plays an important role 
in developing and mature organisms. Morphogenesis during development and homeostasis 
in mature stages are mainly due to apoptosis. In addition apoptosis eradicates cells 
containing cellular and genetic damage and eliminates pathogen infected cells (85). 
Apoptosis is a complex and genetically controlled method of cell death. Vast numbers of 
factors may stimulate apoptosis. Environmental stimuli and cell damage initiate a train of 
signals effecting regulatory proteins including the BCL-2 family, inhibitors of apoptosis 
proteins, and components of death receptor signalling systems. Cell death is controlled by 
these proteins and is carried out by a set of cysteine proteases known as caspases (85).   
Apoptosis occurs in single, scattered cells. The chromatin becomes dense and transforms to 
large granular masses that border with the nuclear membrane. The nucleus becomes 
convoluted and large. The nuclear granules become coarse and abnormally scattered. 
Alongside nuclear alterations, cytoplasm is affected. The cytoplasm becomes condensed 
and translucent cytoplasmic vacuoles develop. Usually blunt protuberances are observed 
on the cell surface. The integrity of many cellular organelles remains intact. Due to 
condensation of the cytoplasm, the organelles become crowded. By this stage, the nucleus 
is broken up into condensed chromatin fragments; some are surrounded by a double 
membrane (81). 
 During the final stages of apoptosis, the protuberances on the cell membrane are detached 
from the cell membrane and form membrane-bound apoptotic bodies. The apoptotic bodies 
of different composition and size enter the intercellular tissue spaces and are mainly 
phagocytised by tissue cells or monocellular phagocytic system. Some may enter the 
adjacent lumen. Due to engulfment of apoptotic bodies, inflammation is not detected 
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during this process. The apoptotic bodies within the phagosome are digested by primary 
and secondary lysosomes and undergo a similar process as cell necrosis (81).  
In culture, apoptotic cells are not phagocytosed. These cells are detached from the adjacent 
cells and float in the medium. The plasma membrane is eventually permeabilised and 
secondary necrosis occurs (87) (figure 1.2.). Various assays have been developed to detect 
apoptosis at different stages of progression and a number of these assays applied in this 
work are described in section 1.9. 
 
1.8.3. Autophagy 
Autophagy is a highly complex process (91) during which, the cell digests itself (85) and 
the cytoplasmic components are degraded in lysosomes (91). 
Although there are three types of autophagy- macroautophagy, microautophagy, and 
chaperon mediated autophagy- the term autophagy usually describes macroautophagy (91). 
Macroautophagy is divided into induced macroautophagy during which, amino acids are 
produced in response to starvation and the constitutive turnover of the cytosolic component 
occurs during basal macroautophagy (92). 
Autophagy has many physiological and pathological roles (figure 1.3). By engulfing 
damaged or unwanted proteins and organelles it has influence on intracellular clearance 
(86, 91). During embryogenesis and morphogenesis, autophagy has been detected. For 
example intersegmental muscles are eliminated by this process (86). In mature organisms, 
autophagy along with apoptosis and necrosis influences homeostasis (85). In addition, 
autophagy plays an important role in cell death (86), elimination of microorganisms, 
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antigen presentation, and tumour suppression (92). There are four stages to completion of 
autophagy (86) (figure 1.3).  
(1) Autophagy induction and cargo packaging. Various environmental (high 
temperature, low oxygen) and intracellular factors (damaged organelles) may induce 
autophagy (93). However, the main and typical inducer of autophagy is lack of nutrients 
and starvation (86, 91). Autophagy is induced in an attempt to provide nutrients by 
digesting macromolecules. A unique, flat, and Golgi cistern like membrane called 
phagophore or isolation membrane, sequesters cytoplasmic components such as organelles 
(91).  
(2) Formation and completion. Cytoplasmic components are engulfed completely by a 
double membrane organelle formed from autophore and known as an autophagosome. The 
selection of cytoplasmic constituents is random, although autophagosomes have the ability 
to recognise some proteins and organelles (91). 
(3) Ducking and fusion. The formed autophagosome binds to lysosomes and the inner 
membrane of the autophagosome, then the cytoplasmic material is digested by lysosomal 
hydrolases.  
(4) Breakdown. The monomeric units formed from macromolecule degradation are 
transferred back to the cytoplasm to be reused. It has been suggested that energy is 
produced during autophagy with the amino acids reused in tricarboxylic acid (TCA) cycle. 
However, this stage has not yet been fully established (91).  
Although apoptosis leads to cell death and autophagy contributes to cell survival (93), a 
number of genes and functions involved in apoptosis and autophagy overlap. Hence these 
two procedures coordinate and they can modify and regulate the activity of each other (86, 
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93). Autophagy may promote or inhibit tumourgenesis. Inactivation of autophagy genes 
may increase tumourgenesis. During cancer development these genes may be deactivated 
by tumourgenesis promoting genes. Autophagy by promoting cell death and regulating cell 
growth may prevent cancer. Therefore, there is potential to develop drugs to manipulate 
autophagy pathways. However, further research is required to determine when or how to 
activate or deactivate autophagy in an attempt to have the best effect on tumours (93).  
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Figure 1.3. Autophagy pathway and its many functions. Autophagy is stimulated by 
metabolic stress or cancer therapies. Autophagosome sequesters cytoplasmic material and 
fuses with lysosome, forming an autolysosome. Degradation of cytoplasmic material 
generates free fatty acids and amino acids, which can result in energy production, protein 
synthesis, or removal of harmful proteins. Autophagy can cause cell death by self- 
cannibalism and/or apoptosis (93). 
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1.8.4. Cell Cycle and Cell Cycle Control 
The cell cycle is highly regulated, comprising of a series of steps leading to division of the 
parental cell to two daughter cells with identical chromosomes. Cell proliferation is very 
important in normal development and it is controlled by timing of DNA replication and 
mitosis. Loss of cell cycle control may result in cancer development. 
The cell cycle is divided into four phases (figure 1.4). During the first phase known as G1, 
the cell synthesises RNA and proteins. DNA synthesis and chromosome replication occurs 
in the S phase and mitosis takes place after G2 phase in M stage of the cell cycle. Most 
differentiated cells in multi-cellular organisms leave the cell cycle and enter a stage known 
as G0. These cells may survive in this stage from a few days to the life time of the 
organism.  
Regulation of the cell cycle occurs by hetrodimeric protein kinases. These proteins are 
formed from a regulatory subunit known as cyclin and a catalytic subunit called cyclin- 
dependent kinase (CDK). There are three major cyclin-CDK complexes regulating 
progression through phases of the cell cycle; G1, G2, and mitotic cyclin-CDK complexes 
(figure 1.4).  
The regulatory effects of these complexes are carried out by phosphorylation of the 
targeted proteins. For example one of the substrates of G1 cyclin-CDK complex is Rb 
protein. This protein is a product of Rb tumour suppressor gene. Activation of this protein 
results in cell halt at restriction point (late G1) and cell cycle arrest. Attachment of the Rb 
to transcription factor E2F, results in binding of deacetylase complex. Deacetylation of 
histone results in transcriptionally inactive chromatin. In contrast, phosphorylation of Rb 
protein liberates E2F and transcription of genes required for entry to S phase is activated. 
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In most cancers Rb protein is deactivated due to mutation or abnormalities in 
phosphorylation.  
There are various check points at different stages of the cell cycle to ensure the 
chromosome is intact and cell phase is completed before the next phase is begun. For 
example, one of the check points identifies DNA damage caused by chemical agents and 
irradiation, which results in cell cycle arrest until the damage is repaired. Arrest in G1 and 
S phase prevents copying of damaged bases to the new cells and arrest in G2 phase 
provides the opportunity to fix the DNA double strand breaks. p53 is a tumour suppressor 
protein causing G1 and G2 arrest in cells containing damaged DNA. p53 is a transcription 
factor with a short half life, which is degraded by proteasomes after binding to Mdm2. 
Phosphorylation by protein kinases such as ATM (ataxia telangiectasia mutated) and ATR 
(ATM and Rad 3 related) prevents p53 degradation. Accumulation of p53 and increase in 
transcription activity of this protein leads to encoding of genes such as p21
CIP
. This gene 
inhibits the activity of cyclin-CDK complexes. Consequently cells are arrested in G1 and 
G2 until DNA is repaired. In situations when DNA damage is extreme, p53 activates genes 
inducing apoptosis (94). 
Increased knowledge of cell cycle and cell cycle control may improve our understanding of 
the mechanisms of the anti-tumour drugs effecting the cell cycle and may provide useful 
information for designing new drugs.  
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Figure 1.4. Cell cycle process and cell check points. The cell cycle is controlled by G1, S-
phase, and mitotic cyclin-dependent kinase complexes (Green). Ubiquitin ligase complexes 
SCF and APC polyubiquitinate S phase inhibitors, securing and mitotic cyclins for 
degradation by proteasomes. Proteolysis of these substrates activates the relevant cyclin-
CDK complexes, leading to cell cycle progression (94). 
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1.9. Cell Death Assessment 
As previously described, different pathways of cell death have certain morphological and 
biochemical features that can be the basis of their identification and distinction. 
Morphological characteristics can be visualised by light or electron microscopy and other 
features that are not readily visible by microscopy can be investigated by various available 
assays. In this section a brief description of techniques used during the following chapters 
in order to identify cell death has been described. 
   
1.9.1. Light and Electron Microscopy 
Cell shrinkage, membrane blebbing, chromatin condensation, DNA fragmentation and 
formation of apoptotic bodies; all representing morphological features of apoptosis can be 
identified by microscopy. Features representing necrosis such as cell swelling, membrane 
rupture, dispersed and fragmented chromatin are also visible by microscopic techniques. In 
addition, cell ultra-structural features can be visualised by electron microscopy and 
alterations to the cell organelles such as nuclei and mitochondria due to cell death can be 
identified. 
 
1.9.2. Light Microscopy Analysis of Haematoxylin and Eosin stained Cells 
Although the haematoxylin and eosin (H&E) staining technique is not a specific method 
for cell death detection, it is a common histopathology method that provides information 
on morphological features of the cell, specifically the nucleus. The cell nucleus and 
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cytoplasm are reasonably distinguished by haematoxylin and eosin dyes, respectively and 
the morphological features of the cells are studied by light microscopy. During this method 
of staining, the cell nucleus is stained blue and the cytoplasm becomes red-purple. 
 
1.9.3. 4΄, 6-diamino-2-phenylindole Staining     
4΄,6-diamino-2-phenylindole (DAPI) is a blue fluorescent dye and useful for nuclear 
counter-stain for multicolour fluorescent techniques. DAPI preferentially attaches to the 
double strand DNA specially the AT clusters of the minor grove (95). DAPI can be excited 
with a xenon or mercury-arc lamp or with a UV laser. The maximum excitation of this dye 
is 358 nm and the emission maximum is 461 nm. As this dye can transfer through the 
intact membrane of viable cells, it can be useful for examining the morphological features 
of the cell nucleus and to identify viable, apoptotic and necrotic cells based on their nuclear 
characteristics.   
 
1.9.4. Trypan Blue Exclusion  
The viability of cells can be examined by exclusion of trypan blue. Apoptotic cells retain 
their membrane integrity to the final stages. Therefore viable cells and apoptotic cells 
exclude trypan blue whereas cells at late stages of apoptosis and necrotic cells have 
impaired cell membranes and are not able to exclude the dye and are stained (96). 
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1.9.5. Detection of Nucleosomal DNA Fragments on Agarose Gel 
Electrophoresis 
Activation of endogenous endonuclease in apoptotic cells results in cleavage of DNA in 
linker regions between the nucleosome cores (81). A ladder pattern of approximately 180-
200 bp integer multiples are detected on gel electrophoresis of the extracted DNA from 
apoptotic cells (figure 1.5). The detected ladder pattern is a hallmark of apoptosis in most 
cell types (96). 
 
 
 
 
Figure 1.5. The biochemistry of DNA fragmentation during apoptosis and the appearance 
of 180-200 bp DNA fragments as ladder pattern on gel electrophoresis (97). 
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1.9.6. Flow cytometry Analysis of AnnexinV-FITC Labelled and Propidium 
Iodide Stained Cells 
Viable cells maintain their membrane phospholipid asymmetry by Mg
2+
/ATP-dependent 
translocases, known as flippases (98). The choline containing phospholipids such as 
phosphatidylcholine (PtCho) and sphingomyelin are based mainly in the outer layer of the 
plasma membrane and aminophospholipids, PEth and phosphatidylserine (PS) are located 
at the inner layer (figure 1.6) (99, 100).   
 
 
 
Figure 1.6. Schematic representation of loss of cell membrane asymmetry during early 
stages of apoptosis. PS molecules are located in the inner layer of the cell membrane 
(orange circles). During apoptosis they are translocated to the outer membrane. FITC 
labelled annexin V has high affinity to the exposed PS (100). 
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During apoptosis PS is translocated to the outer layer of the cell membrane. PS exposure 
occurs at early stages of apoptosis induction and remains on the surface until the late 
stages. PS exposure is a marker for detection of dying cells by macrophages in vivo (100). 
The affinity of annexin V, bound to fluorescein-isothiocynate (FITC), to a negatively 
charged phospholipid such as PS (101, 102) is used for detection of apoptotic cells. As it is 
not able to penetrate the membrane and bind to viable cells, viable and apoptotic cells are 
distinguished from each other (figure 1.6). Although PS is translocated on the cell surface 
of apoptotic cells, the membrane integrity is intact. However, the membrane of necrotic 
cells is impaired and permeable hence, these cells can be recognised by uptake of DNA 
binding dyes such as propidium iodide (PI) (96). Simultaneous addition of DNA stains 
assists in differentiating necrotic and apoptotic cells (100).    
 
1.10. The Use of Cisplatin to Induce Cell Cycle Arrest and Cell 
Death  
Cisplatin (cis-dichlorodiammineplatinum) is a platinium drug developed clinically in the 
1970s (103) and it is used for treatment of a number of tumours including glioblastoma 
(104). Cisplatin induces apoptosis or cytostasis followed by apoptosis depending on the 
dosage used. In a study by Qin et al. on human hepatoma cell lines, low doses of cisplatin 
resulted in apoptosis in Hep3B cells (with deleted p53) and caused transient arrest in G1 
followed by progression and block of cell growth in the S phase of the cell cycle in HepG2 
cells. A number of HepG2 cells then progressed to apoptosis. At high doses of cisplatin, 
apoptosis was detected in both Hep3B and HepG2 cells (105). This property makes 
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cisplatin a useful agent in the study of cell cycle arrest and cell death and it is a clinically 
relevant choice for a member of brain tumours.  
Effects of cisplatin on morphology and cycling of rat glioma cells (C6) was investigated by 
Mares et al. Enlargement of cells was detected in exposed cultures and restructuring of the 
processes within the cells due to cisplatin resulted in reduced proliferation rate and 
progression to cell death at later stages of treatment (106).  
Cisplatin enters the cells through transmembrane channels. The mechanisms of action of 
these channels are not well understood. After entry, cisplatin becomes strongly hydrated 
and chloride concentration decreases in order to form species with a positive charge. This 
results in interaction of cisplatin with nucleophils (107). Therefore, nucleophil sites such as 
DNA, RNA, proteins, membrane phospholipids, cytoskeletal microfilaments and thiol-
containing molecules interact with cisplatin. Only 1% of the cisplatin within the cells 
interact with DNA and although other sites interacting with cisplatin contribute to 
cytotoxicity, the interactions between DNA and cisplatin have been identified as the main 
target leading to death in exposed cells. If the detected DNA damage is not repairable 
apoptosis is induced. A number of different adducts including inter- and intra-strand cross-
links and DNA-protein cross-links are formed in the DNA (103) (figure 1.7). The most 
common adduct is an intra-strand cross-link between adjacent guanines (108). Unrepaired 
DNA adducts may lead to cell arrest and progression to apoptosis (103, 104). 
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Figure 1.7. Cisplatin interaction with DNA. (a) inter-strand cross-link. (b) 1,2-intra-strand 
cross-link. (c) 1,3-intra-strand cross-link. (d) protein-DNA cross-link (103). 
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1.11. Objectives of the Thesis 
The main objective of this work is to identify general markers of cell stress and specific 
markers of cytostasis and cell death in rat BT4C glioma cell line by studying alterations of 
a number of metabolites and lipids in response to cell stress using 
1
H HR-MAS NMR 
spectroscopy. In addition morphological and molecular assays are used to identify the type 
of cell death contributing to the detected alterations.  
In the chapters 3 and 4, BT4C cells are exposed to a common anti-tumour drug cisplatin 
for various time intervals. A number of assays are carried out to determine the viability 
status of the cisplatin exposed cells and 
1
H HR-MAS NMR is performed on cells using a 
Varian 600MHz nanoprobe to identify alterations induced by cisplatin in these cells. The 
main focus of chapter 3 is to identify 
1
H HR-MAS NMR metabolite alterations in the 
cisplatin exposed cells and chapter 4 focuses on identifying alterations in the 
1
H HR-MAS 
NMR visible lipid signals and recognising the origin of the detected lipid resonances.  
In chapter 5, starvation is used to induce necrosis in BT4C cells, allowing a comparison in 
the pattern of lipids and metabolites caused by two different types of stress stimuli. In this 
Chapter cells are maintained in a substrate free medium for various time intervals. The 
type of cell death is identified with various assays and the alterations in lipid and 
metabolite profiles of these cells are investigated by 
1
H HR-MAS NMR.   
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CHAPTER 2 
MATERIALS AND METHODS 
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2.1. Rat Glioma Cells 
All solutions and equipment used for cell culture were obtained sterile. Work was carried 
out under sterile conditions in a cytox II laminar flow cabinet (Gelman Sciences Ltd., 
Northampton, UK). The work surface and equipments used were sterilised with 70% ISM 
(industrial methylated sprit) where required. 
 
2.1.1. Cell Culture 
Rat glioma cell line, BT4C, was cultured in 75 cm
2
 flasks with filter-vented caps (IWAKI, 
Appleton Woods Ltd, Birmingham, UK) and maintained in 20 ml Dulbecco‟s modified 
Eagles medium (DMEM F:12), without L-glutamine  (GIBCO, Invitrogen Co, Paisley, 
UK) supplemented with 10% (v/v) foetal calf serum (PAA Laboratories, Somerset, UK), 
1% 200 mM  L-glutamine (100x) (GIBCO), and 1.8% MEM non essential amino acid 
solution (100x) (Sigma-Aldrich, Dorset, UK). The cells were incubated at 37°C in a 
humidified atmosphere (5% CO2, 95% air). Cells were seeded at approximately 2 x 10
6
 
cells/Flask and were passaged on day 2 of culture.    
                      
2.1.2. Detachment of Confluent Cells 
Once the cells were 70-80% confluent, the medium was removed using sterile plastic 
pipettes. The cells were then washed with phosphate buffered saline (Dulbecco‟s A PBS, 
Oxoid, Hampshire, UK). PBS was removed and 1 ml accutase in PBS with 0.5 mM EDTA 
(TCS Cellworks, Buckingham, UK) was added to the flask. The flask containing the cells 
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was placed in the 37°C humidified chamber for 1-2 minutes until the cells had started to 
lift off from the flask surface. 9 ml of supplemented DMEM F:12 (without L-glutamine) (1 
in 10 dilution)  was added to the cells to stop the action of accutase and to wash the surface 
of the flask. The cells were then gently pipetted up and down few times to separate them 
from each other. 1 ml of the cell suspension was removed to a new 75 cm
2
 flask and 
DMEM medium was added to make the volume to 20 ml. The cells and fresh medium 
were gently mixed and the flask was placed in the humidified chamber (37°C, 5% CO2).   
 
2.1.3. Cell Counting 
After the cells were detached from the flask, one drop (~20 µl) of the cell suspension in 
PBS/medium was added to the chamber of a Neubauer haemocytometer (Ruling 1/400 
mm
2
, cell depth 0.1 mm+1%; Hawksley, Sussex, UK) by a sterile plastic transfer pipette. 
The cells were then counted under a Nikon TMS microscope (Nikon Ltd, Kingston upon 
Thames, UK) with the 40 x magnification lens (Figure 2.1).  
 
2.1.4. Cell Cryopreservation 
The detached cells with accutase were frozen down for future use. The cells were 
resuspended in supplemented DMEM F:12 (without L-glutamine) medium containing 10% 
(v/v) cryoprotectant (sterile DMSO, Dimethyl sulfoxide, Sigma-Aldrich). The number of 
cells was counted in the cell suspension using the method described previously (section 
2.1.3.). Approximately 1 ml of the cell mixture was aliquoted into 2 ml cryovials (Nunc, 
Roskilde, Denmark). The cryovials were placed in a freezing container (Fisher Scientific 
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Nalgene, Loughborough, UK) and were kept in -70°C freezer for 24 hours and were then 
placed in liquid nitrogen. 
 
 
 
 
Figure 2.1. A schematic image of a Neubauer haemocytometer slide and the grids used to 
count the cells. 
 
 
2.1.5 .Cell Culture from Frozen Samples 
Cryovials containing cells were removed from liquid nitrogen and placed in a waterbath at 
37°C for 1-2 minutes to thaw. The cryovials were wiped with IMS prior to opening. The 
content of each vial was then transferred to 75cm
2
 flask. 10 ml supplemented DMEM F:12 
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(without L-glutamine) was added slowly to the flasks. This was done to provide the time 
and the opportunity for the cells to become adapted to the new temperature. The cell 
suspension was mixed and the volume was made up to 20 ml using the supplemented 
medium. The flasks were then placed in 37°C humidified chamber (5% CO2). 
 
2.1.6.Cytospin Preparation and Cytocentrifuge 
Shandon cytospin (Shandon, Thermo Scientific, Loughborough, UK) (figure 2.2) was used 
to separate and place a monolayer of cells on slides while preserving their integrity. The 
slides were assembled with filter cards (Shandon, Thermo Scientific) and cytofunnel 
disposable sample chambers (Shandon, Thermo Scientific) and they were then placed in 
cytoclips (Shandon, Thermo Scientific) (figure 2.3). 100 µl of cell suspension containing 
1x10
6
 cells was placed in each cytofunnel. The samples were then spun at 500 rpm for 5 
minutes in room temperature.  
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Figure 2.2. A Shandon cytospin (Shandon, Thermo Scientific). 
 
 
 
 
Figure 2.3. Image of assembled filter card, cytofunnel, and cytoclip.   
 
 
49 
 
2.2. Cell Stress Stimuli 
2.2.1.Cisplatin 
Cisplatin was used to induce cell cycle arrest in BT4C cells. 100 mg of this drug was 
purchased from Sigma-Aldrich (P4394) in powder form. 
 
2.2.1.1 .Preparing Cisplatin for Cell Treatment 
To prepare a stock solution of cisplatin with the concentration of 200 mM, 100 mg of this 
drug was dissolved in 1.66 ml sterile DMSO. 100 µl aliquots of the prepared cisplatin 
stock solution were placed in sterile microcentrifuge/eppendorf tubes and stored in -70°C 
freezer.  
The cells were exposed to 50 µM cisplatin for various times. On the day of treatment, the 
required amount of cisplatin stock solution was removed from the freezer and thawed at 
room temperature. Cisplatin was further diluted to a concentration of 50 µM in fresh, 
supplemented DMEM F: 12 (without L-glutamine).  
 
2.2.1.2. Adding Cisplatin to the Cells  
Cultured cells were incubated overnight. Medium was removed and the cells were washed 
with PBS. Fresh DMEM F:12 (without L-glutamine) containing 50 µM cisplatin was 
added to the cells. The flasks containing cultured cells were further incubated for 12, 24, 
48, or 72 hours in humidified chamber (5% CO2) at 37°C. 
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2.2.2. Culture in Phosphate Buffered Saline 
To cause necrosis in BT4C cells, starvation was induced by culturing cells in PBS (1x) 
(without CaCl2 and MgCl2) (GIBCO, Invitrogen Co). BT4C cells were cultured in DMEM 
F:12 medium overnight. The medium was then removed and 20 ml PBS (without CaCl2 
and MgCl2) was added to the flasks. The cells were further incubated in humidified 
chamber (37°C, 5% CO2) for 4, 6, 12, 18, or 24 hours.   
 
2.3. Harvesting Cells for Morphological and Molecular Assays 
After exposing the cells to PBS or cisplatin for a specific duration; the medium containing 
cisplatin or the PBS was removed from the flask and transferred to 50 ml sterile centrifuge 
tube. The cells were washed with PBS and the used PBS was transferred to the 50 ml tube. 
1 ml accutase was added to the flask and after covering the cells with accutase the flask 
was placed in the humidified chamber (37°C, 5% CO2) for 1-2 minutes until the cells were 
lifted off from the flask surface. Using the medium in the tube, the cells were transferred to 
the 50 ml centrifuge tube. The cell suspension containing attached and floating cells was 
then centrifuged at 250 rpm (Centrifuge 5804, Eppendorf, Cambridge, UK) for 6 minutes 
at room temperature.  The supernatant was then removed and the cells were resuspended in 
10 ml PBS and pipetted up and down few times. The cell suspension was centrifuged again 
at room temperature for 6 minutes at 250 rpm. After centrifuging, PBS was removed and 
the cell pellet was resuspended again in fresh PBS. In total the cells were washed three 
times with PBS. The cells were then ready to be used in various morphological and 
molecular assays as discussed in section 2.5.  
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2.4. 
1
H HR-MAS NMR Spectroscopy 
2.4.1. Harvesting Cells for 
1
H HR-MAS NMR Spectroscopy 
After each time point the medium or PBS was removed from the flask and transferred to a 
sterile 50 ml centrifuge tube. The cells were then washed with ice-cold PBS (without 
CaCl2 and MgCl2) and scraped from the flask surface. The detached cells were added to the 
tube and centrifuged for 6 minutes at 250 rpm. The supernatant was removed and the cell 
pellet containing floating and previously attached cells was washed 3 times with 10 ml ice-
cold PBS (without CaCl2 and MgCl2). The number of cells in 10 ml ice-cold PBS (without 
CaCl2 and MgCl2) was counted according to the method described in section 2.1.3. To 
prevent biochemical degradation, approximately 50x10
6
 cells (from two 75 cm
2
 flasks) 
were snap frozen and kept in liquid nitrogen. Cells were kept on ice during preparation. 
 
2.4.2. 
1
H HR-MAS NMR Spectroscopy Sample Preparation 
Just before performing 
1
H HR-MAS NMR spectroscopy, the prepared cells in cryovials 
were removed from liquid nitrogen and thawed in room temperature. 32 µl of harvested 
cells and 8 µl (20% of the total volume placed in the nanoprobe) dideuterium monoxide 
(D2O; Sigma-Aldrich) were placed in a 4-mm gHX nanoprobe (Varian NMR Inc, Oxford, 
UK). After thawing, the cells were placed on ice and were kept on ice until the samples 
were inserted in the pre-cooled NMR probe. The approximate time from thawing to 
experimentation was 5 minutes. 
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2.4.3. Performing 
1
H HR-MAS NMR Spectroscopy 
A vertical bore Varian 600 MHz (14.1T) spectrometer (figure 2.4) with a three channel 
Inova console running VNMRj software, was used to record magic angle spinning spectra 
of prepared samples (The Henry Wellcome Building, The University of Birmingham). The 
samples were spun at 2500 Hz at a probe temperature of 0.1ºC corresponding to a rotor 
temperature of 6.7ºC (methanol calibration).  
A pulse and acquire sequence with a repetition time of 3.3s was applied to collect 256 
scans. The repetition time of 3.3s was used based on the previous work carried out by Peet 
et al. (167). They examined the use of prolonged repetition time in 
1
H MRS of a human 
neuroblastoma cell line. Peet et al. increased the repetition time to 8.3s and discovered an 
average increase of less than 10% in the metabolite concentration. This study indicated 
prolonging the repetition time has little effect on the metabolite concentration and 
increases the experimental time. Therefore, a repetition time of 3.3s was used here; 
resulting in 14 minutes acquisition time for each sample.  
The receiver band width was 7200 Hz with 16k complex points in the free induction decay. 
The rotor was spun at a speed of 2500 Hz. Tuning and matching was carried out on each 
sample and a presaturation pulse (1 sec) at water frequency was applied to suppress the 
water signal before applying a 90º read pulse. 
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Figure 2.4. A Varian 600 MHz spectrometer at the Henry Wellcome Building, The 
University of Birmingham. 
 
 
2.4.4. Assigning and Quantitating 
1
H HR-MAS NMR Signals 
The spectra were phased and referenced to the creatine signal at 3.03 ppm and the peaks 
were assigned and quantified. Metabolites were quantified using an automated algorithm, 
TARQUIN (109) and 
1
H HR-MAS NMR visible lipids were quantified using a modified 
version of this algorithm. The TARQUIN algorithm measures the metabolite and lipid 
quantities by fitting a series of simulated individual metabolite and lipid signals to the 
experimentally acquired data (figure 2.5 and table 2.1). The relative quantity of 
1
H HR-
MAS NMR visible lipids was determined in relation to the macromolecule signals at 0.94, 
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1.68, and 3.00 ppm. The assignment of the resonances at 0.94, 1.68, and 3.00 ppm to 
macromolecules rather than mobile lipids follows assignments by Opstad et al. (110) and is 
substantiated by their broad nature, strong correlation with each other and invariance 
during cisplatin treatment and PBS exposure when compared with other spectral features.  
The relative concentrations of metabolites were measured in relation to the sum of the 
metabolites in each sample. For in vivo studies, absolute quantification is difficult to attain 
and metabolites are usually quoted as a ratio relative to other metabolites or tissue water. In 
this work metabolite alterations during cell death were investigated. Deregulation of 
osmolyte homeostasis followed by increase in cell volume or cell shrinkage are features 
associated with necrosis and apoptosis, respectively. Therefore, water may alter between 
investigations. Where serial 
1
H MRS is undertaken to investigate response to treatment, 
relative metabolite concentrations are likely to be the most consistent measurements. 
Hence this approach was used in this in vitro work to measure the relative concentration of 
the metabolites. 
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Figure 2.5.A typical spectrum of BT4C cells. The TARQUIN algorithm was used to 
identify and quantitate metabolite and lipids in the spectrum. The residual spectrum is 
shown at the top section of the image. 
(Preprocessed spectrum                 Fit to the preprocessed spectrum  
The individual fitted components of the basis set            ) 
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metabolite Moiety 
Chemical 
Shift (ppm) 
metabolite Moiety 
Chemical 
Shift (ppm) 
Acetate 
 
1.90 Glutamine 
 
3.75 
Alanine 
 
3.77 
 
 
2.12 
 
 
1.46 
 
 
2.1 
Aspartate 
 
3.89 
 
 
2.43 
 
 
2.80 
 
 
2.45 
Choline 
 
3.18 
 
 
6.81 
 
 
4.05 
 
 
7.52 
 
 
3.50 GPC Glycerol 3.6 
Creatine 
 
3.02 
 
 
3.67 
 
 
3.91 
 
 
3.9 
 
 
6.64 
 
 
3.87 
Glutathione Glycine 3.76 
 
 
3.94 
 
 
7.15 
 
Choline 4.31 
 
Cystein 4.50 
 
 
3.65 
 
 
2.92 
 
 
3.21 
 
 
2.97 Glycine 
 
3.54 
 
 
8.17 Lactate 
 
4.09 
 
Glutamate 3.76 
  
1.31 
 
 
2.15 
Myo-
inositol 
 
3.52 
 
 
2.14 
  
4.05 
 
 
2.51 
  
3.52 
 
 
2.56 
  
3.61 
Glutamate 
 
3.74 
  
3.26 
 
 
2.03 
  
3.61 
 
 
2.12 PC 
 
4.28 
 
 
2.33 
  
3.64 
 
 
2.35 
  
3.2 
Taurine 
 
3.42 PEth 
 
3.97 
  
3.24 
  
3.21 
Guanidioacetate 3.70 Scyllo-Inositol 3.34 
   
Succinate 
 
2.39 
       
Table 2.1. Metabolites identified by TARQUIN algorithm. The chemical shifts assigned to 
each of the metabolites and J-coupling properties are used to identify signals of a spectrum.  
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2.5. Assessing Cell Viability and Cell Death 
2.5.1. Trypan Blue Staining 
The cells were harvested as described in section 2.3. The cell pellet was resuspended in 10 
ml PBS. A volume of cell suspension in PBS was mixed with an equal volume of 0.4% 
solution of trypan blue (Sigma-Aldrich). The suspension was pipetted a few times and was 
left at room temperature for 5 minutes. Using a sterile transfer pipette one drop (~20 µl) of 
the cell mixture in trypan blue was placed on a Neubauer haemocytometer and the number 
of dead and viable cells in 3 independent samples was counted as described in section 
2.1.3. Microscopic observation of trypan blue stained samples distinguishes viable cells as 
bright, unstained cells and the dead cells as dark and blue stained cells (figure 2.6). 
 
 
 
Figure 2.6. Trypan blue staining of BT4C cells. Dead cells appear darker and viable cells 
are identified as brighter, unstained cells. Only a few of the dead cells are labelled in this 
image. 
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2.5.2. Haematoxylin and Eosin Staining 
2.5.2.1. Preparing Cells for H&E Staining 
The cells were harvested as described in section 2.3 and resuspended in 10 ml PBS. The 
number of cells was then counted according to the method described in detail in section 
2.1.3 and the volume of the cell suspension was adjusted so the number of cells was 
approximately 1x10
7 
per ml. 100 µl of the cell suspension was then placed on slides using 
a cytocentrifuge (described in section 2.1.6). The slides were then immediately fixed in 
70% ice-cold methanol (Sigma-Aldrich) and air dried. 
 
2.5.2.2. H&E staining of the prepared slides 
The slides were placed in haematoxylin for 5 minutes and then in acid ethanol few times 
for few seconds. After the slides were washed with water they were placed in eosin for 30 
seconds. The samples were dehydrated in series dilutions of alcohol (95 and 100%) and 
were placed in 100% alcohol and xylene (50:50). Finally using a mounting solution cover-
slips were mounted on the prepared slides. 
With H&E dyes, viable, apoptotic and necrotic cells are distinguished based on their 
morphological features. Apoptotic cells contain condensed and fragmented chromatin and 
necrotic cells have diffused nuclei and at later stages disrupted cell membranes. The viable 
cells are distinguished from dead cells by their homogenous chromatin (figure 2.7). The 
percentages of viable, apoptotic, and necrotic cells were calculated in 500 random cells in 
each prepared sample.  
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Figure 2.7. Haematoxylin and eosin staining of BT4C cells. Morphological characteristics 
of the cell nuclei help in identifying necrotic and apoptotic cells. Apoptotic cells contain 
fragmented nuclei and necrotic cells have dispersed nucleus.  
 
 
2.5.3. Transmission Electron Microscopy 
2.5.3.1. Sample Preparation for Transmission Electron Microscopy  
The cells were harvested and washed according to the procedures discussed in section 2.3. 
After removal of PBS, the cell pellet was fixed in 2.5% gluteraldehyde (TAAB 
Laboratories Equipment Ltd, Aldermaston, UK) solution in PBS, overnight. The samples 
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were post-fixed in 1% osmium tetroxide (OsO4; Oxkem, Reading, UK) for 1 hour at room 
temperature. They were then dehydrated in alcohol gradients.  
 
2.5.3.2. Cutting the Samples and observing with Transmission Electron Microscopy 
The samples were embedded in epoxy resin (TAAB Laboratories Equipment Ltd) by 
routine procedures. Ultrathin sections of approximately 90 nm were prepared and placed 
on copper grids. The sections were then stained in saturated uranyl acetate (TAAB 
Laboratories Equipment Ltd) and lead citrate (TAAB Laboratories Equipment Ltd) 
solution in 0.1 mol low carbonate NaOH (VWR International, Lutterworth, UK). The 
samples were observed by Zeiss-EM 109 transmission electron microscope (Zeiss Ltd, 
Welwyn Garden City, UK) and images were captured using a TFP (trans-fibre optic 
photography) camera system (Zeiss Ltd).    
 
2.5.4. Flow Cytometry Analysis of Annexin V-FITC labelled and Propidium 
Iodide stained Cells  
ApoDETECT annexin V-FITC kit was purchased from Zymed laboratories (Invitrogen 
Immunodetection) and the supplied protocol was used to label and stain the samples.  
The cells were harvested as described in section 2.3. They were resuspended in the 1 x 
binding buffer (part of the kit, 10 mM hepes/NaOH, pH 7.4, 140 mM NaCl, 2.5 mM 
CaCl2). The cell density was adjusted to 2x10
6
 cells/ml. After adding 10 µl FITC 
conjugated Annexin V to 190 µl of the cell suspension in binding buffer, the samples were 
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mixed gently and incubated in the dark for 10 minutes at room temperature. 200 µl 1 x 
binding buffer was added to the cells and the suspension was centrifuged at 3000 rpm for 1 
minute. Supernatant was removed and the cells were resuspended in 190 µl 1 x binding 
buffer. 10 µl of 20 µg/ml PI (part of the kit) was added and the cells were transferred to 
FACS tube and flow cytometry was immediately performed. The samples were evaluated 
on a Coulter EPICS XL analyser (Beckman Coulter Ltd, High Wycombe, UK) and the data 
were analysed using FlowJo (version 7.5, Tree Star Inc, Oregon, USA) (111). 
 
2.5.5. Detecting DNA Fragmentation 
In apoptotic cells, endogenous endonuclease cleaves DNA in between nucleosomes and in 
the linker regions. The fragments of 180-200 bp are visualised as a typical ladder pattern 
on gel electrophoresis and are convincingly good end markers of apoptosis in cells (81, 89, 
96, 102).  
 
2.5.5.1. Preparing Buffers 
A litre of 10 x TBE buffer was made form 108 g tris base, 55 g boric acid, and 40 ml 0.5 M 
EDTA (pH 8). A 0.5 x dilution of this buffer was made with deionised water and was used 
for DNA electrophoresis. The compounds were purchased from Sigma-Aldrich. 
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2.5.5.2. Preparing the Sample and Running the Agarose Gel 
Cells were harvested as described in section 2.3. 20 million cells were resuspended in 10 
ml PBS. The samples were centrifuged at 2300 rpm for 3 minutes. The supernatant was 
removed and the cell pellet was vortexed vigorously in the remaining supernatant. While 
the samples were vortexed, 3 ml cell lysis solution (Puregene, Gentra Systems, Crawley, 
UK) was added to the cell suspension. 15 µl RNase A (Puregene, Gentra Systems) solution 
was added and the samples were mixed by inverting the tube 25 times. The cells were then 
incubated at 37ºC for 30 minutes. The samples were then removed and placed on ice for 5 
minutes. After adding 1 ml protein precipitation solution (Puregene, Gentra Systems), the 
samples were vortexed vigorously for 20 seconds. Cell suspension was centrifuged at 4600 
rpm for 10 minutes. The supernatant containing DNA was removed from the protein pellet, 
and 3 ml 100% isopropanol (Sigma-Aldrich) was added to the supernatant. The samples 
were mixed and DNA became visible by inverting the tube gently 3-5 times. Clump DNA 
was removed to an eppendorf tube and centrifuged at 130 x 100 rpm for 3 minutes. After 
removal of the supernatant, 1 ml 70% ethanol (Sigma-Aldrich) was added to the DNA. The 
tube was inverted 3-5 times to wash the DNA pellet. Ethanol was then removed by 
centrifuging the samples for 1 minute at 130 x 100 rpm. The sample was air dried for 20 
minutes and then 50 µl DNA hydration solution (Puregene, Gentra systems, UK) was 
added. To rehydrate the DNA, the tubes were placed in 50ºC hot block for 10 minutes and 
were kept at room temperature over night. DNA was diluted with deionised water and 
stained with bromophenol blue (3',3",5',5"-tetrabromo phenolsulfonphthalein) prior to 
loading on the gel. 1kb DNA ladder (Invitrogen Co) was used as positive control and 
deionised water was used as negative control. 
64 
 
1% agarose gel (Sigma-Aldrich) was made in 0.5 x TBE solutions containing (2x10
5
:1) 
ethidium bromide (10 mg/ml). The gel was placed on a plastic tray in an electrophoresis 
tank and submerged just beneath 0.5 x TBE. The samples were placed on the gel and were 
run for 90 minutes at 120 V. The DNA fragments were observed by ultraviolet light. 
 
2.6. Assessing Cell Cycle Phase Distribution 
To identify cell cycle distribution in untreated and cisplatin exposed cells, samples were 
stained with PI and analysed by flow cytometry. The position of the cells in the cell cycle 
can be determined by measuring the amount of DNA present in the samples. The amount 
of DNA in cells at G2 or M stage is twice the concentration of DNA detected in cells at G0 
or G1 phase and the detected amount of DNA in cells at S phase is variable. In this 
method, PI is attached to double strand DNA and the amount of the stained DNA is 
measured by flow cytometry.  
 
2.6.1. Preparing Buffers and Solutions 
DNase solution was made by dissolving DNase (Deoxyribonuclease I from bovine 
pancreas; Sigma-Aldrich) in SMT buffer (20 mM trizma base (2-Amino-2-
hydroxymethyl)-1,3-propanediol), 250 mM sucrose, 5 mM MgCl2, pH=7.4; Sigma-
Aldrich) at a concentration of 500 µg/ml. The prepared DNase solution was aliquoted and 
stored at -20°C. On the day of testing the solution was thawed at room temperature. RNase 
solution was made from ribonuclease A (from bovine pancreas; Sigma-Aldrich) and PBS 
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(without CaCl2 and MgCl2) at a concentration of 50 µg/ml. The aliquots were stored in -
20°C freezer and thawed at room temperature on the day of the experiment. To make DNA 
staining solution with a concentration of 1 mg/ml, PI (Sigma-Aldrich) was dissolved in 
PBS (without CaCl2 and MgCl2). The solution was then filtered using a 0.22 µm syringe 
tip filter. This was carried out to remove solid and undissolved stain. The prepared staining 
solution was kept in the dark and at 4°C.     
 
2.6.2. Preparing Untreated Samples for Flow Cytometry Analysis 
Untreated samples were harvested as described in section 2.3. The number of cells was 
counted and approximately 1x10
6
 cells were fixed. While the cells were vortexed 
vigorously, 10 ml 70% cold ethanol (Sigma-Aldrich) was added. The first 1-2 ml was 
added drop by drop.  The cells were kept as cold as possible during this procedure. As soon 
as the fixative was added to the cells, samples were placed in -20°C freezer for at least half 
an hour. The cells were then centrifuged at 1750 rpm for 5 minutes. The fixative was 
removed and the cells were washed with 10 ml PBS. After centrifuging at 1750 rpm for 5 
minutes supernatant was removed and the cells were resuspended in 1 ml RNase solution 
(Final concentration used 50 µg/ml).  The suspension was then transferred to a FACS tube 
and incubated for 20 minutes at 37°C. The samples were removed and 50 µl PI solution 
was added.  The samples were gently mixed and incubated for a further 10 minutes at room 
temperature.  
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2.6.3. Preparing Cisplatin Exposed Cells for Flow Cytometry Analysis 
Cisplatin treated cells were harvested according to the procedures described in section 2.3. 
Cells were counted and 1x10
6
 cells were removed to an eppendorf tube. Cells were 
resuspended in 1 ml DNase solution with final concentration of 500 µg/ml and were 
incubated at 37°C for 15 minutes. The tubes containing cells and the DNase solution were 
then placed in an ice bath. The cells were kept on ice for 10 minutes to inactivate DNase. 
The cells were then centrifuged at 1000 rpm for 5 minutes and the DNase solution was 
removed. Cells were vortexed vigorously in the remaining DNase. To fix the cells, 10 ml 
ice cold 70% ethanol was added while vortexing. The first 1-2 ml of the fixative was added 
drop by drop. By placing the samples on ice in between vortexing, the cells were kept as 
cold as possible. After adding the fixative, the tubes containing the cells were placed in -
20°C freezer for at least 30 minutes. After 30 minutes, the cells were centrifuged at 1750 
rpm for 5 minutes and the supernatant was removed. The cells were then washed with 10 
ml PBS and resuspended in 1 ml RNase solution giving a final concentration of 50 µg/ml. 
Samples were transferred to FACS tubes and placed in 37°C chamber for 20 minutes. 50 µl 
PI was added after 20 minutes and the cells were mixed gently. The samples were analysed 
by flow cytometer after 10 minutes incubation in room temperature.    
 
2.6.4. Flow cytometry analysis 
Cell cycle distribution was evaluated on a Coulter EPICS XL analyser (Beckman Coulter 
Ltd). The samples were run and the analysis was stopped automatically after 20,000 
events. Both histogram and listmode files were saved and the cell cycle distribution was 
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determined as percentages after selecting the single cell cycle option of the multicycle 
software version 3 (Phoenix Flow Systems, San Diego, USA) (figure 2.8). 
 
 
 
Figure 2.8. Cell cycle analysis platform of multicycle software version 3. A control sample 
is used to define the G1 and G2 ranges. The defined regions are used to fit the treated 
samples and the optimal fits are presented as fraction of cells in each phase of the cell 
cycle.  
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2.7. Nile Red and DAPI Co-Staining 
Nile red or Nile blue oxazone (9-diethylamino-5H-benzo[α]phenoxazine-5-one) is an 
excellent dye for staining lipids (112, 113). Therefore, it was used in this work to detect the 
presence of cytoplasmic lipid droplets. The yellow-golden lipid droplets in cell cytoplasm 
were detected at wave lengths of 450-490 nm with fluorescent microscopy. At these wave 
lengths, neutral lipids such as TGs, cholesterol, and cholesterol esters are detectable (113); 
indicating the nature of the identified lipid droplets. The faint background in Nile red 
images represents hydrophobic proteins and amphipathic lipids such as phospholipids in 
the cell membrane (113). These structures fluoresce red in the wave lengths of 540-580 nm 
using a Texas red excitation filter. 
 In order to determine the viability status of the cells containing cytoplasmic lipid droplets 
and to identify the type of cell death (apoptosis/necrosis) in these cells, DAPI dye in 
combination with Nile red was used. The advantage of Nile red and DAPI co-staining is 
that it allows the status of the cells containing lipid droplets to be determined. Viable cells 
are distinguished by their homogenous nuclei and necrotic cells have inhomogeneous and 
dispersed chromatin. Cells with condensed and fragmented nuclei were identified as 
apoptotic cells.  
 
2.7.1. Preparing Nile Red and DAPI Stock Solutions 
A stock solution of 10 mg/ml Nile red (Sigma-Aldrich) in acetone was made. After 
removal of undissolved stain with filter papers, the staining solution was kept in the dark at 
4°C. On the day of staining, Nile red was further diluted to a concentration of 1 µg/ml in 
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PBS. 1 mg/ml DAPI (Sigma-Aldrich) in PBS was made as stock solution and was passed 
through a filter paper.  The prepared solution was stored at 4°C in the dark. A dilution of 
0.2 µg/ml was made in PBS on the day prior to staining. 
 
2.7.2. Nile Red and DAPI Staining Procedures 
Nile red staining was carried out based on the procedures described by Greenspan et al. 
(113). 
Cells were harvested according to the methods described in detail in section 2.3. The cells 
were washed with PBS and counted. Approximately 10
7
 cells were resuspended in 1 ml 
Nile red with a concentration of 1 µg/ml. The mixture was placed in the dark for 5 minutes. 
The samples were then centrifuged at 3000 rpm for 1 minute. Nile red was removed and 1 
ml PBS was added to the cells. After mixing gently, the cells were placed in the dark for 1 
minute. The samples were then centrifuged at 3000 rpm for 1 minute. The supernatant was 
removed and the cell pellet was resuspended in 0.2 µg/ml DAPI. Samples were incubated 
in dark for 30 minutes. The stained cells were then placed on the slides using a 
cytocentrifuge, according to the procedures described in section 2.1.6. 
 
2.7.3. Fluorescence Microscopy and Image Capture 
The slides were visualised using a Nikon E600 microscope coupled to a SPOT RT KE 
colour 3 shot CCD camera (Diagnostic Instruments Inc, Michigan, USA) for image 
capture. Nile red stained lipid droplets were observed with a FITC (B-2A) filter set, using 
an excitation wave length of 450-490 nm. A DAPI UV (UV-2A) filter with excitation 
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wavelength of 340-380 nm was used to detect DAPI stained nuclei of untreated and treated 
cells. Images were captured at 40 x magnification monochromatically and in grey scale. 
Nile red and DAPI signal were pseudo-coloured red and blue respectively before 
combining.  
 
2.7.4. Image Processing 
ImageJ 1.38X software (National Institute of Health, Maryland, USA) was used to process 
the images in gray scale and prior to merging. Using this software, the images were 
calibrated and their brightness and contrast were adjusted.  
The threshold levels of the cell and lipid droplet area were identified from the gray scale 
Nile red images and were assigned based on their detection on the threshold scale. The 
average threshold of cells in three gray scale Nile red images were used to identify and 
measure the cell and lipid droplet area. Measurements were performed on individual cells 
and results were reported as percentage of cell area covered by lipid droplets. Lipid area 
was measured in 500 random cells in each prepared sample (figure 2.9). To measure lipid 
droplet diameter similar procedures were used. The measurements were carried out using 
ImageJ software and on gray scale images. The diameter of each lipid droplet in the 500 
randomly selected cells was measured by drawing a line across the lipid droplet and the 
results were reported in micrometer (µm) (figure 2.10). 
The viability status of the cells containing lipid droplets was determined based on the 
morphological characteristics of DAPI stained nucleus of each cell. The viable cells 
contain homogenous nuclei and the necrotic cells have inhomogeneous nuclei with 
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dispersed chromatin. Apoptotic cells are detected as cells with condensed and fragmented 
nuclei. The numbers of apoptotic, necrotic, and viable cells were counted in 500 cells of 
each prepared sample and the results were reported as percentages. A second observer 
independently validated the results. 
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Figure 2.9. ImageJ 1.38X platform for threshold detection. The threshold of the lipid 
droplet and the whole cell were selected based on where they were identified. The selected 
areas were then measured and the percentage of the cell area covered by lipid droplets was 
calculated.  
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Figure 2.10. ImageJ 1.38X platform for image measurements. The diameter of a lipid 
droplet is measured by drawing a line across the droplet and measuring the length of the 
line.  
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2.8. Statistical Tests 
The data in this work were analysed using SPSS version for windows (Version 16, SPSS 
Inc, Chicago, USA). One-way ANOVA test was performed on the data after testing the 
normal distribution of the data and the homogeneity of the variance. The significant level 
was set at 5% and the significant differences presented are between control samples and 
each time point tested.  
 
2.9. Principal Component Analysis 
Principal component analysis (PCA) is a statistical technique used for analysing and 
finding patterns in large data sets such as metabolite data collected from MRS. PCA 
transforms a number of possibly correlated variables to a smaller number of uncorrelated 
variables known as principal components in order to identify their similarities and 
differences. Principal component findings can be presented as scores and loading plots. 
Scores plots project the data in the new coordinate system which is based on the PC values 
and the loading plots define the size of the contribution of each original data to the PCs. 
The first principal component accounts for a maximal amount of variability in data as 
possible and the next principal components represent as much as the remaining variability 
as possible. Therefore, an overview of the data can be achieved by the score plots of the 
two most important PCs. 
PCA was performed on 
1
H HR-MAS NMR metabolites of cisplatin treated cells of various 
time points and on the metabolite data set of starved cells of different durations. In 
addition, PCA was performed on combined metabolite data of cisplatin treated and starved 
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cells. The PCA scores were shown using scores and loading plots. By performing PCA on 
the 
1
HR-MAS NMR metabolite data sets it is easier to determine which metabolites 
contribute more to the variance between groups and which metabolites distinguish and 
separate the groups from each other. PCA of the cisplatin exposed/starved cells and the 
control cells identifies the metabolites that are most different between the control and drug 
treated/starved cells. In addition, PCA of the combined data identifies metabolites that 
distinguish the two conditions from each other. The average metabolite quantities of each 
time point in starved and cisplatin treated cells were calculated and PCA was performed 
using the MATLAB statistics Toolbox implementation of PCA (Mathworks Inc, 
Cambridge, UK) (114). 
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CHAPTER 3 
1
 H HR-MAS NMR METABOLITE ALTERATIONS  
OF CISPLATIN INDUCED GROWTH ARREST IN 
RAT BT4C GLIOMA CELLS 
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3.1. Introduction 
Physiological, developmental, and pathological changes alter metabolites in biological 
system such as cells, tissues and organisms (3, 4). Therefore, analysis of metabolite 
profiles has the potential to be used in monitoring treatment. MRS with its ability to be 
used as part of clinical imaging (3, 115), is one of the few techniques applied to monitor 
metabolite profiles directly in patients (8) and to determine metabolite alterations during 
treatment with the aim of identifying early biomarkers of successful therapy to monitor 
tumour treatment response in vivo (3, 20). Poor spectral resolution of in vivo MRS makes 
ex vivo NMR of tissue (62) and in vitro studies of cells and tissue (62, 116) invaluable aid 
to the in vivo studies. Studies on cell lines have the particular advantage of allowing the 
effects of drugs on a pure population of tumour cells to be studied, giving valuable 
information on the metabolite changes and molecular pathways involved.  
1
H HR-MAS NMR is used in this chapter and in the following chapter to investigate rat 
glioma BT4C cells treated with cisplatin. The BT4C glioma cell line has a rapid growth 
rate and consistent structure and features. It also has the advantage of being used as a 
xenograft model for in vivo MRS studies of cell death (20, 21, 41, 50, 61, 62, 117). In vitro 
NMR of intact cells allows quantitation of several metabolites that may not be detectable in 
vivo and the identified metabolite profile may provide improved insight into the altered 
biochemical pathways during treatment (118). In the following chapters in vitro 
1
H HR-
MAS NMR has been used to identify markers of cell stress and cell death. 
Cisplatin is a chemotherapeutic drug that has shown efficacy against primary CNS 
malignancies (119) such as glioma (104). This drug inhibits the cell cycle and results in 
apoptotic cell death. Therefore, cisplatin is an excellent model of cell cycle arrest prior to 
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apoptosis allowing the potential of metabolite profiles to act as early indicators of 
treatment response. In this chapter, 
1
H HR-MAS NMR metabolite alterations in response 
to cisplatin exposure are identified and in the following chapter 
1
H HR-MAS NMR visible 
lipid changes in growth arrested cells are investigated.  
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3.2. Methods 
BT4C cells were treated with 50 µM cisplatin for 12, 24, 48, or 72 hours. Cell viability was 
examined by trypan blue and H&E dyes. The type of cell death induced by cisplatin was 
investigated via flow cytometery of annexin V-FITC labelled and PI stained cells and the 
detection of DNA fragments on gel electrophoresis. The effects of cisplatin on cell cycle 
distribution were identified by flow cytometry examination of PI stained cells.  
 To identify the metabolite and lipid profile of cisplatin exposed BT4C cells, 
1
H HR-MAS 
NMR spectroscopy was performed. The detected levels of metabolites and lipids were 
quantitated relative to sum of metabolites and macromolecules, respectively. PCA was 
carried out on the HR-MAS metabolite data to identify alterations occurring in cisplatin 
exposed cells. Changes in metabolite profile of cisplatin exposed cells are discussed in this 
chapter. In chapter 4 alterations in lipid profile of these cells have been studied. Three 
independently prepared samples were examined at each time point for each of the tests 
carried out (figure 3.1). 
 
 
 
 
 Figure 3.1. Flow chart of the methods used in chapter 3 and 4. 
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3.3. Results 
3.3.1. Preliminary work 
As part of the preliminary work for this study, trypan blue dye was used to investigate 
BT4C cell death at various concentrations of cisplatin and at different time intervals. 
Approximately 50% cell death occurred after 72 hours exposure to 50 µM cisplatin and the 
majority of cells were viable at shorter time intervals. With high percentages of viable cells 
at shorter time points of 12, 24, 48 hours and almost half of the cells being dead after 72 
hour cisplatin exposure, for the experiments presented in this thesis, BT4C cells were 
exposed to 50 µM cisplatin for time intervals of 12, 24, 48, or 72 hours (Table 3.1).  
 
 
12 hrs 24 hrs 48 hrs 72 hrs 
25 µM 7+4.73 9+1.53 7+2.31 10+2.65 
50 µM 16+3.40* 17+4.65* 22+6.51* 51+17.47** 
75 µM 24+4.04* 50+9.71** 58+6.24** 60+14.93** 
100 µM 61+8.54* 68+13.11** 80+15.50** 81+18.04** 
      
Table 3.1. Preliminary work was carried out to identify the percentage of dead cells after 
exposure to various concentrations of cisplatin and at different time intervals. Half of the 
cells were dead after 72 hrs exposure to 50 µM cisplatin and majority of the cells were 
viable at shorter time intervals. Therefore, this concentration of cisplatin was used in the 
experiments described in chapters 3 and 4 The percentages of dead cells are presented as 
mean percentage+SD (n=3,*p<0.05; **p<0.001).   
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3.3.2. Morphological Analysis of Cell Death: Trypan Blue and H&E 
Staining  
Trypan blue and H&E staining (figure 3.2) revealed that the majority of cells are 
morphologically viable up to 48 hours cisplatin exposure but after 72 hours, the percentage 
of dead cells increased significantly (figure 3.3).  
The number of dead cells revealed by trypan blue dye increased from 5.5+2.5% in 
untreated cells to 22+6.5% (p<0.05) in 48 hours cisplatin exposed cells, showing that the 
majority of the cells are viable at this time point (results from 3 independent samples). 
H&E staining confirmed this finding detecting 25+0.5% dead cells (p<0.001) at 48 hours 
cisplatin exposure (results of 500 random cells from each 3 independent samples). 
However, at the longer cisplatin exposure time of 72 hours, increasing number of cells 
showed features of cell death. 50.8+17.5% and 63.2+6.8% dead cells were detected in 
these samples by trypan blue and H&E staining, respectively (p<0.001).  
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Figure 3.2. Images of control and cisplatin treated cells after various time intervals (12, 24, 
48, 72 hrs), stained with H&E. The arrows are pointing to apoptotic cells and the arrow 
heads are showing the necrotic cells. The scale bars represent 20 micrometer. 
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Figure 3.3. Percentages of dead cells revealed by H&E (♦) and trypan blue (■) staining in 
untreated and after 12, 24, 48, or 72 hrs cisplatin exposure in BT4C cells.  The error bars 
are SEM and the significant differences are identified by comparing each time point with 
the control, untreated samples (n=3 for each time point, *p<0.05, **p<0.001).  
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3.3.3. Molecular Analysis of Cell Death: Flow cytometry Analysis of 
Annexin V-FITC Labelled and PI Stained Cells and Detection of DNA 
Laddering 
Flow cytometry analysis of annexin V-FITC labelled and PI stained cells of cisplatin 
exposed samples revealed a trend in the number of identified apoptotic and necrotic cells 
(figure 3.4). With longer exposure to cisplatin, there was a tendency towards increasing 
numbers of apoptotic and necrotic cells. However, even up to 48 hours cisplatin exposure, 
the percentage of apoptotic and necrotic cells were 15.0+15.4% and 9.3+5.7%, 
respectively. The flow cytometry findings confirmed the low numbers of dead cells 
detected via microscopic analysis of stained samples.  
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Figure 3.4. Percentages of apoptotic and necrotic cells revealed by annexin V-FITC flow 
cytometry. To confirm the high percentages of viable cells and low numbers of dead cells 
detected by trypan blue and H&E staining after 12, 24, or 48 hrs cisplatin exposure, cells 
were labelled and stained with annexin V-FITC and PI. The cells were then analysed with 
flow cytometer and the data were processed with FlowJo (n=3 for each time point).  
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In the DNA laddering experiments, the ladder pattern was not detected on the gel 
electrophoresis of cisplatin exposed BT4C cells until 72 hours of drug exposure when a 
weak DNA pattern became visible (figure 3.5). 
 
 
 
Figure 3.5. Detecting DNA fragmentation. DNA was harvested from untreated and 
cisplatin treated BT4C cells (12, 24, 48, or 72 hrs) according to the procedures described in 
the method section. The DNA harvested from the cells was run on gel electrophoresis to 
determine presence of the ladder pattern, a typical late stage marker of apoptosis (A. 1: 
negative control, 2,9: positive control, 3,6: untreated cells, 4,7: 48 hrs cisplatin exposed 
cells, 5,8: 72 hrs cisplatin exposed cells; B.1: negative control, 2: positive control, 3,6: 
untreated cells, 4,7: 24 hrs cisplatin exposed cells, 5,8: 48 hrs cisplatin exposed cells).  
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3.3.4. Cell Cycle Phase Distribution 
To further investigate the status of cells at early stages of cisplatin treatment, the cell 
growth phase was identified by staining the cells with PI and examining them with flow 
cytometry as described in chapter 2 section 2.6. Cell cycle measurements clearly indicated 
accumulation of the cells in G1 Phase of the cell cycle and cell growth arrest in this phase 
in treated BT4C cells (Table 3.2). 
 
 
 
 
 
 
 
Table 3.2. Cell cycle phase distribution. Cells were stained with PI and analysed by flow 
cytometry. In order to identify cell cycle phase distribution the data were analysed with 
multicycle software. The percentages of cells in each stage of the cell cycle are presented 
as mean percentage+SD (n=3,*p<0.05; **p<0.001). 
 
 
 G1 S G2/M 
control  40.2+1.3 50.5+1.1 9.3+0.3 
12h  40.4+1.8 48.3+1.7 11.3+1.1 
24h  50.3+1.4** 42.0+1.0** 7.0+0.7* 
48h  58.4+1.3 ** 39.3+1.5** 2.3+2.8* 
72h  44.2+16.4 54.5+17.2 1.3+1.1** 
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With longer exposure to 50 µM cisplatin, the percentage of cells accumulating in the G1 
stage of the cell cycle increased and after 24 and 48 hours exposure to the drug, the 
percentage of the cells in the G1 phase increased significantly from 40.2+1.3% in untreated 
samples to 50.3+1.4% and 58.4+1.3%, respectively (p<0.001). The proportion of cells in 
the S phase of the cell cycle decreased with longer exposure to the drug, reaching 
39.3+1.5% after 48 hours of cisplatin exposure (p<0.001). However, the percentages of 
cells in G1 and S phase of the cell cycle did not alter after 72 hours of cisplatin exposure 
compared to the control samples. This may indicate that the cells progressed through the 
stages of cell cycle which resulted in cell death and an increase in the number of dead cells. 
 
3.3.5. 
1
H HR-MAS NMR Metabolite Alterations 
1
H HR-MAS NMR identified several metabolites in cisplatin exposed cells (figures 3.6 and 
3.7).  
The relative concentration of each of the metabolites was calculated to the sum of all the 
metabolites. The data showed quantitative time dependent changes in the metabolite profile 
of BT4C cells in response to cisplatin exposure (table 3.3). Significant differences in the 
relative levels of metabolites are given in table 3.4. 
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Figure 3.6. 
1
H HR-MAS NMR spectra of BT4C cells following cisplatin exposure. (A) 0.5 
to 4.5 ppm region. Metabolites labelled are as follows:  1- lactate, 2-alanine, 3- glutamate, 
4- succinate, 5- glutamine and aspartate, 6- creatine, 7- choline, 8- GPC and PC, 9- taurine, 
10- scyllo-inositol, 11- glycine, 12- myo-inositol, 13- Guanidioacetate.  
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Figure 3.7.  Choline containing region. Metabolites labelled on the control spectrum are as 
follows: 1- choline, 2- phosphocholine, 3- glycerophosphocholine, 4- taurine, 5- 
phosphatidylcholine 6- glycine). 
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Table 3.3. Relative concentrations of 
1
H HR-MAS NMR detectable metabolites in 
untreated and cisplatin exposed cells for different times (12, 24, 48, or 72 hrs). The results 
are presented as mean+SD. Three samples at each condition were analysed.   
 
 
 
Metabolites Untreated cells 12h 24h 48h 72h 
Acetate 8.08E-04+7.04E-04 1.97E-04+3.42E-04 0.00E+00+0.00E+00 1.45E-03+1.80E-03 0.00E+00+0.00E+00 
Alanine 9.90E-02+4.30E-03 9.71E-02+5.92E-03 7.61E-02+7.32E-03 6.64E-02+1.81E-03 4.45E-02+1.08E-02 
Aspartate 4.58E-02+6.64E-03 2.33E-02+4.83E-03 4.39E-02+8.67E-03 4.40E-02+1.11E-02 2.74E-02+3.22E-03 
Choline 1.28E-02+3.09E-03 1.14E-02+1.24E-03 9.07E-03+2.72E-03 1.33E-02+6.19E-03 1.57E-02+3.81E-03 
Creatine 1.34E-02+3.87E-03 1.10E-02+4.59E-04 9.50E-03+2.75E-03 9.23E-03+2.11E-03 1.24E-02+1.64E-03 
Glutathione 7.01E-02+3.19E-02 8.07E-02+6.03E-03 8.55E-02+6.79E-03 8.28E-02+3.72E-03 5.56E-02+8.27E-03 
Glutamate 2.59E-01+2.91E-02 1.69E-01+4.26E-02 1.69E-01+2.64E-02 1.77E-01+1.16E-02 1.35E-01+6.98E-03 
Glutamine 2.06E-02+6.43E-03 2.22E-02+4.64E-03 2.17E-02+6.16E-03 5.43E-02+2.71E-03 4.31E-02+4.23E-02 
GPC 3.87E-02+2.11E-02 6.70E-02+6.47E-03 1.02E-01+3.34E-03 1.20E-01+9.08E-03 1.06E-01+2.45E-02 
Glycine 1.09E-01+2.15E-02 4.28E-02+4.97E-03 3.56E-02+3.41E-03 3.97E-02+1.68E-03 3.43E-02+3.20E-03 
Lactate 1.06E-01+3.00E-02 2.82E-01+1.30E-02 2.85E-01+4.10E-02 2.75E-01+1.36E-02 3.73E-01+4.74E-02 
Myo-Inositol 7.79E-03+1.13E-02 2.24E-03+2.74E-03 0.00E+00+0.00E+00 0.00E-00+0.00E+00 2.64E-05+4.57E-05 
PC 8.38E-02+7.63E-03 7.24E-02+9.52E-04 4.57E-02+1.34E-03 2.67E-02+5.29E-03 2.62E-02+2.92E-03 
PEth 0.00E+00+0.00E+00 3.07E-02+5.00E-02 2.95E-02+5.10E-02 0.00E+00+0.00E+00 1.05E-02+1.81E-02 
Scyllo-Inositol 3.13E-03+1.38E-03 2.66E-03+5.44E-04 1.02E-03+5.18E-04 3.62E-04+1.01E-04 1.64E-04+2.69E-04 
Succinate 5.59E-03+2.60E-03 5.15E-03+6.86E-04 5.62E-04+8.77E-04 0.00E+00+0.00E+00 1.41E-03+2.41E-03 
Taurine 7.82E-02+1.93E-02 2.93E-02+4.49E-03 2.35E-02+5.14E-03 2.24E-02+2.86E-03 2.71E-02+2.15E-02 
Hypo-Taurine 2.40E-02+5.54E-03 1.40E-02+3.18E-03 1.14E-02+5.77E-03 1.31E-02+7.35E-03 2.30E-02+2.13E-03 
Guanidioacetate 4.05E-03+4.38E-03 1.86E-02+9.85E-04 3.04E-02+3.08E-03 2.63E-02+5.71E-03 2.23E-02+1.47E-02 
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Table 3.4. Significant 
1
H HR-MAS NMR alterations detected in relative concentrations of 
the metabolites in response to cisplatin exposure. (↑) represents an increase in relative 
metabolite levels and (↓) represents a decrease in the relative metabolite levels compared 
to control cells (*p<0.05, **p<0.001). 
 
 
The relative levels of PC, succinate, glutamate, glycine and taurine deceased with longer 
exposure to cisplatin. Changes occurred within 12 hours of treatment in taurine, glutamate 
and glycine. Increases were detected during treatment in lactate and GPC, with lactate 
relative levels being increased at 12 hours.  
 
Metabolites 
Cisplatin exposed cells 
12h 24h 48h 72h 
PC   **↓ **↓ **↓ 
GPC   **↑ **↑ **↑ 
Lactate  **↑ **↑ **↑ **↑ 
Alanine   *↓ **↓ **↓ 
Succinate   *↓ *↓  
Glycine  **↓ **↓ **↓ **↓ 
Glutamate  *↓ *↓ *↓ **↓ 
Taurine  **↓ **↓ **↓ **↓ 
PC/GPC   *↓ *↓ *↓ 
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The scores plot for the PCA of the metabolite profiles is presented in Figure 3.8.A. The 
first and second principal components, account for 36% and 19% of the variance, 
respectively. Cisplatin exposure is associated with an increase in the first principal 
component and this change occurs early in the time course. From the loadings plot for 
principal component 1(figure 3.8.B) cisplatin exposure is associated with changes in many 
metabolites, the most prominent changes being decreases in PC, glycine, succinate, taurine, 
alanine, glutamate,  and scyllo-inositol with an increase in GPC and lactate.  
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Figure 3.8. PCA of the quantities of 19 NMR fitted metabolites of cisplatin exposed cells. 
(A) Scores plot. (B) Loadings for principal component 1. (C) Loadings for principal 
component 2. 
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3.4. Discussion 
H&E and trypan blue staining of BT4C cells showed low numbers of apoptotic and 
necrotic cells up to 48 hours of cisplatin exposure and revealed an increase in the 
percentage of dead cells in samples exposed to cisplatin for 72 hours. H&E images showed 
that the majority of cells after 12, 24, and 48 hours of cisplatin exposure represent 
morphological characteristics of viable cells and cells representing morphological 
characteristics of apoptosis increased after 72 hours cisplatin exposure. Flow cytometry 
analysis of annexin V-FITC labelled and PI stained cells and the lack of ladder pattern on 
gel electrophoresis confirmed the staining and microscopic findings. Further investigation 
into the status of cisplatin exposed BT4C cells with PI and flow cytometry revealed growth 
arrest in these cells. Therefore, presuming that the contribution from the low numbers of 
apoptotic and necrotic cells is small, the 
1
H HR-MAS NMR metabolite alterations seen 
represent changes occurring in cell metabolism during cell cycle arrest and prior to 
apoptosis.  
There is a possibility that the NMR spectra represent contribution from metabolites with 
vast alterations within apoptotic and necrotic cells. However, low numbers of apoptotic 
and necrotic cells were detected by morphological and molecular techniques and an 
association was detected between 
1
H HR-MAS metabolite alterations and increasing 
numbers of growth arrested cells detected by flow cytometry analysis of PI stained cells.  
There is a possibility that large changes in few metabolites would influence the relative 
concentration of the detected metabolites. However, using the sum of all the metabolites in 
calculating the relative concentration of individual metabolites reduces this effect. 
* * 
* 
 
* * 
* 
* 
* 
* 
** 
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Furthermore, previous studies are in agreement with findings described here. Hakumaki et 
al. (50) examined the extracts of BT4C glioma cells by MRS. TSP (trimethylsilyl-2,2,3,3-
tetradeuteropropionic acid) was used as an external reference and the metabolite levels 
were measured relative to TSP. Although different references were used in this study and 
the work presented in this chapter, similar metabolite alterations were detected. For 
example a decrease in PC relative levels and an increase in GPC relative concentrations 
were detected in both studies. This confirms that large metabolite changes and the 
application of sum of all the metabolites do not influence the metabolite profiles. In 
addition the metabolite changes detected by Hakumaki et al (50) were associated with cell 
cycle arrest prior to apoptosis and previous studies have described low PC/GPC ratios as 
markers of cell cycle arrest (8,50,63). These metabolite changes were similar to the work 
described here and provide further evidence for the detected association between 
metabolite alterations of cisplatin exposed cells and growth arrest prior to apoptosis. 
 
3.4.1. Choline Containing Metabolite Alterations 
A decrease in relative levels of PC and an increase in GPC relative levels were detected in 
growth arrested BT4C cells in response to cisplatin exposure and this resulted in a reduced 
ratio of PC/GPC. Changes in the PC/GPC ratio, represent alterations in choline 
homeostasis (8) and PtCho turnover (1, 63). An increase in PC/GPC ratio has been 
associated with increased phospholipid turnover and PtCho synthesis (63) and a decrease 
in this ratio prior to apoptosis has been suggested as an indicator of growth arrest (50). A 
reduced PC level has been identified in response to chemotherapy in tumour tissue samples 
and has been proposed as an early biomarker of effective treatment in vivo (63).  
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PC and GPC are compounds of phospholipid metabolism. PC is used in phospholipid 
synthesis and it is produced during phospholipid degradation by phospholipase C (PLC) 
activity. Phospholipase A2 (PLA2) and lysophospholipase produce GPC from the final 
product of the Kennedy pathway, PtCho (Fig 3.9). During this process, fatty acids are 
formed which may be used in production of TG. The activity of phopholipases has been 
suggested as a possible reason underlying PC and GPC alterations (8, 78).  
Decreased levels of PC were also detected in ganciclovir treated BT4C cells (50) and TNF-
α treated breast cancer cells (80). The detected alteration in BT4C cells were associated 
with widespread growth arrest (50) and the PC levels of treated breast cancer cells were 
identified prior to apoptosis and in cells arrested in G0/G1+S phases of the cell cycle (80). 
The detected increase in GPC levels of prostate carcinoma cells was also associated with 
cell cycle arrest (48). However the association of CCMs with cell growth arrest has not 
been well established.  
Individual CCMs are not discriminated by in vivo 
1
H MRS and the different changes in 
GPC and PC may explain the conflicting reports in the literature on tCho as a marker for 
tumour response to treatment. The sum of GPC, PC, and Cho signals did not alter 
significantly in cisplatin treated BT4C cells, consistent with the in vivo studies of treatment 
response in gliomas (20, 61, 62). This and the previously discussed results emphasise the 
role of in vitro studies in understanding the alterations of the individual metabolites 
contributing to the CCM signal and the possible altered biochemical pathways.  
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Figure 3.9. Phospholipid metabolism. The activities of phospholipase A2 and 
lysophospholipase result in production of GPC and fatty acids and phospholipase C 
activity results in degradation of phosphatidylcholine and production of phosphocholine. 
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3.4.2. Energy Related Metabolite Alterations 
An increase in relative levels of lactate and decreases in alanine, succinate, glycine, and 
glutamate relative levels were detected in growth arrested BT4C cells in response to 
cisplatin exposure. Similar changes in lactate and alanine were identified in INF-γ/TNF-α 
treated human colon adenocarcinoma (HT-29) cells. An increase in lactate and a decrease 
after an initial increase in alanine were reported in these cells prior to the appearance of 
apoptosis (69). The detected alterations are likely to represent changes to energy 
metabolism.  
In non-malignant cells glucose is converted to pyruvate in the cell cytosol through the 
glycolysis pathway. The pyruvate produced is then transferred through the mitochondrial 
membrane and it is further metabolised during TCA cycle. The NADH and FADH2 
produced during this process are donated to the electron acceptors across the inner 
mitochondrial membrane and via oxidative phosphorylation, high levels of ATP are 
produced. In the absence of oxygen or electron acceptors pyruvate is converted to lactate 
by the enzyme lactate dehydrogenase. During this pathway less ATP is produced (120).  
In tumours, glucose metabolism is altered and glucose is converted to lactate in the 
presence of oxygen. This is known as the Warburg effect (121). Although oxidative 
phosphorylation is more efficient in producing ATP, glycolysis can generate energy in a 
more rapid rate (122) and the processes involved can be beneficial to tumour cell survival 
and growth (123-125). Growing cells produce ATP mainly from glucose (126) and use 
lipids and amino acids for synthetic procedures whereas vegetative cells have a limited 
glucose uptake and are able to use a variety of metabolites to produce energy (9). As 
growth is inhibited in BT4C cells there is a possibility that the metabolites are not used in 
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synthetic pathways and are redirected to energy metabolism resulting in the detected 
alterations of lactate, the TCA cycle intermediates (eg. succinate), and amino acids (eg. 
glutamate, alanine and glycine) (figure 3.10). 
In addition, by causing inter- and intra-strand cross-links, cisplatin causes damage to the 
DNA structure (103). It is well known that damaged DNA activates a DNA repair enzyme 
known as poly (ADP-ribose) polymerase (PARP). This enzyme consumes NAD and 
depletion of this compound inhibits the activity of a glycolysis enzyme known as 
glyceraldehyde-3-phosphate dehydrogenase (69). Therefore PARP activity inhibits glucose 
dependent ATP production (127) (figure 3.10). Inhibition of glycolysis and conversion of 
glucose to pyruvate may provide another explanation for redirecting metabolites to energy 
metabolism pathways and the detected increase in lactate and decrease in succinate, 
alanine, glycine, and glutamate in an attempt to remain viable.  
Under optimal conditions in a test tube biochemical reactions will reach equilibrium. In 
cells, biochemical pathways are linked together. Product of one pathway may act as a 
reactant for another pathway or it may be secreted from the cell. In biological systems the 
linked pathways are in a steady state and the rate of production is similar to the rate of 
consumption. This prevents accumulation of intermediates and reduces their possible toxic 
side effects. The steady state is disrupted by changes in production or consumption of 
metabolites and their reaction rates. This influences the related pathways and causes 
alterations in their reaction rates and metabolite levels (94). There is a possibility that in 
cisplatin exposed cells glycolysis inhibition causes increases in the rate of other energy 
producing pathways and therefore resulting in high relative levels of lactate and low 
relative levels of amino acids in BT4C cells. 
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Figure 3.10. The metabolite pathways relevant to metabolite alterations in cisplatin 
exposed BT4C cells. Damaged DNA activates poly (ADP-ribose) polymerase, a DNA 
repair enzyme which results in consumption of NAD and inhibition of glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) activity (indicated by a red circle). Hence glucose 
dependent ATP production is inhibited. In this diagram the metabolites with red arrows 
altered significantly with longer exposure to cisplatin in BT4C cells (Ala. alanine, Arg. 
Arginine, Asn. asparagine, Asp. aspartate, Cys. cysteine, Glu. glutamate, Gln. glutamine, 
Gly. glycine, His. histidine, Ile. isoleucine, Leu. leucine, Lys. lysine, Met. methionine, Phe. 
phenylalanine, Pro. proline, Ser. serine, Thr. threonine, Trp. tryptophan, Tyr. tyrosine, Val. 
Valine). 
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Furthermore, several studies suggest that the levels of glycine, taurine, and glutamate are 
markers of malignancy (116, 128, 129). These metabolites are therefore key candidates as 
biomarkers of treatment response. Reports from in vitro studies in brain tumours have 
shown that glycine increases with WHO grade (130-133) and increases between diagnosis 
and relapse (134, 135). In recurrent astrocytoma, higher ratios of alanine, glycine over 
creatine were detected with increase in malignancy (135). In vivo, an increase in glycine 
levels of a rat glioma model was also observed (136). A recent study has also shown that 
glycine can be measured by in vivo MRS at a field strength of 1.5T clinically and that 
glycine concentrations increase with grade in childhood brain tumours (128). The potential 
of glycine in particular to act as a biomarker of both prognosis and treatment response is 
interesting for clinical application and further studies in this area are required. 
 
3.4.3. Taurine Alterations 
The highest levels of taurine are seen in primitive neuroectodermal tumours (137), which 
have very high levels of cell proliferation. A decrease in relative levels of taurine during 
cell cycle arrest would be consistent with this association between taurine and cell 
turnover. However, taurine concentration has been correlated with levels of apoptosis in 
astrocytomas and has been suggested as a clinical monitoring tool for apoptosis in gliomas 
(74). This would at first appear contrary to the presented findings where taurine levels 
decrease with drug treatment and in growth arrested cells.  
Release of taurine and other osmolytes such as K
+
 and Cl
-
 from cells, lead to extrusion of 
water and cell shrinkage which is a distinctive hallmark of early stages of apoptosis (138, 
139). Perhaps taurine accumulates in the surrounding tissue in vivo and in cell cultures is 
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discarded during wash steps. However, after cisplatin exposure few BT4C cells showed 
signs of apoptosis and cell shrinkage and the association of taurine with apoptosis was not 
strictly tested. A full understanding of taurine significance in apoptosis and the 
mechanisms behind its changes is yet to emerge. 
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3.5. Conclusion 
Metabolite alterations of cisplatin exposed rat BT4C glioma cells were investigated as 
potential biomarkers of cell cycle arrest prior to apoptosis.  
A decrease in relative levels of PC and an increase in GPC relative levels were detected in 
BT4C cells following cell cycle arrest induced by cisplatin. PC decrease and GPC increase 
indicate growth arrest in BT4C cells and provide early markers of treatment response in 
these cells. Although PC and GPC relative levels altered, tCho relative level remained 
unchanged. This was similar to previous in vivo studies and further indicated the 
importance of discriminating individual metabolites contributing to the CCM signal. 
With the cell cycle being inhibited in BT4C cells in response to cisplatin exposure, energy 
metabolism is altered in these cells. Increased relative levels of lactate and decreased 
relative levels of succinate, glutamate, alanine, taurine, and glycine were detected in 
growth arrested cells, prior to apoptosis. Since glutamate, glycine, and taurine are novel 
markers of malignancy, the detected decrease in the relative concentration of these 
metabolites may potentially be useful in identifying tumour treatment response.  
Increased taurine levels have been associated with increased cell proliferation. Therefore 
reduced relative levels of taurine detected in cisplatin exposed BT4C cells provide further 
insight into the role of taurine in tumours and may have the potential to be used as a 
marker of growth arrest and treatment response. 
The specificity of the detected metabolite alterations to cell cycle arrest is not known and 
further investigations are required to identify and compare metabolite relative levels of 
growth arrested cells with dead cells. Therefore in chapter 5 alterations of 
1
H HR-MAS 
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NMR profile in response to starvation induced necrosis in BT4C cells are investigated. In 
chapter 5, relative metabolite alterations associated with cell growth arrest and necrosis are 
compared in order to identify general markers of cell stress and specific markers of cell 
necrosis and cell growth arrest prior to apoptosis.  
In addition to metabolites lipid alterations detected by 
1
H MRS have attracted a vast 
interest as potential markers of treatment efficacy and the next chapter is dedicated to 
identifying 
1
H HR-MAS NMR alterations of mobile lipids in response to cisplatin induced 
growth arrest in BT4C cells. Further investigations are carried out to determine the 
association of the detected lipid alterations with cytoplasmic lipid droplet diameter and size 
to further investigate the origin of the 
1
H HR-MAS NMR signals. 
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CHAPTER 4 
1
 H HR-MAS NMR LIPID ALTERATIONS  
OF CISPLATIN INDUCED GROWTH ARREST IN 
RAT BT4C GLIOMA CELLS 
AND 
THE SOURCE OF THE NMR VISIBLE LIPIDS  
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4.1. Introduction  
A number of signals in 
1
H NMR spectra of malignant cells are from elevated levels of 
isotropically tumbling mobile lipids (37, 38). These lipid signals arise from mobile fatty 
acyl chains of TGs, free fatty acids and cholesteryl esters (22) and an increase in their 
levels has been associated with cell death (21, 42, 46, 47, 50, 54, 56), transformed and 
differentiated cells (51), stimulated (43, 44), or quiescent (43, 78) cells. 
This indicates the possibility of similar underlying mechanisms for the detected lipid 
accumulation during various circumstances. Therefore, an increase in lipids during cell 
death is of particular interest, as they have the potential to be used as biomarkers of 
treatment response. Lipid alterations during cell death have been associated in particular 
with apoptosis (48). Several studies have correlated increases in the methylene (CH2) 
moieties of the lipid peak at 1.3 ppm with apoptosis in various drug- treated cell models 
(44, 47, 48, 54). In addition, a number of studies have associated lipid accumulation with 
another method of cell death, necrosis (42, 46, 56). Lipid accumulation in human brain 
tumour biopsies, have been associated with the extent of necrosis (56) but the origin of the 
detected mobile lipids in in vivo MRS is not fully understood (43).   
An increase in lipids has also been identified at early stages of cell death prior to apoptosis 
(44) and during growth arrest (43, 45, 49, 79, 140). If lipid accumulation can be detected 
early on before the occurrence of cell death, then 
1
H MRS lipids may have the potential to 
be used as early biomarkers of cell death and may provide useful information on cellular 
response to treatment.    
The location of fatty acyl chains of NMR detectable lipid signals remains somewhat 
controversial as discussed in chapter 1. Initially membrane associated microdomains (40, 
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52) were identified as the source of lipids, however recent findings point to cytoplasmic 
lipid droplets as the origin of increasing lipid resonances (22, 42-44, 46-49).  
It was shown in the previous chapter (chapter 3) that 50 µM cisplatin exposure of glioma 
BT4C cells results in cell cycle inhibition. In this chapter, experiments are continued on 
these growth arrested cells and the potential of lipid alterations as early biomarkers of anti-
cancer drug therapy is investigated. The Evidence is provided that lipid droplets in the 
cytoplasm of morphologically viable cells are the source of the accumulated NMR mobile 
lipid signals detected in these cells. The accumulation of lipid droplets in cells undergoing 
cell cycle arrest has not been demonstrated previously. 
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4.2. Methods 
1
H HR-MAS NMR was used to determine lipid accumulation in growth arrested rat glioma 
BT4C cells of 3 samples in response to different cisplatin exposure times. The 
1
H HR-
MAS NMR lipid data presented in this chapter and the metabolite data presented in chapter 
3 were obtained from the same cell preparation and the relative concentration of 
metabolites and lipids were measured from similar spectra.  
The combination of Nile red and DAPI dye was used to stain BT4C cells of 3 
independently prepared samples after each cisplatin exposure time to investigate the source 
of 
1
H HR-MAS NMR visible lipids and to determine the viability of the cells in which 
lipid alterations occurs. Further evidence on the morphology of cells containing lipid 
droplets and their viability status was provided by TEM. All assays were carried out on 
three independently prepared samples for each cisplatin exposure time (figure 3.1).  
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4.3. Results 
4.3.1. Nile red and DAPI staining    
Cisplatin exposed cells were co-stained with Nile red and DAPI as described in chapter 2. 
Nile red was used to investigate the presence of lipid droplets in the cytoplasm of cisplatin 
exposed cells and to determine the association between cytoplasmic lipid droplet 
characteristics and the detected 
1
H HR-MAS NMR lipid accumulation using ImageJ 
software. DAPI dye was combined with Nile red to determine the viability status of the 
cells containing lipid droplets and to confirm the presence of lipid droplets in 
morphologically viable cells, determined in the previous chapter to be growth arrested. 
Staining with Nile red dye revealed the presence of lipid droplets in the cytoplasm of 
treated and untreated BT4C cells (figures 4.1.1 and 4.1.2). ImageJ measurements of Nile 
red stained cells showed substantial increases in the percentage of the cell area occupied by 
lipid droplets (figure 4.2) and the lipid diameter (figure 4.3). For each time interval 500 
random cells of 3 independent samples were measured. In untreated, control cells 
22.2+3.6% of the cell area was occupied by lipid droplets and the mean diameter of lipid 
droplets in these cells was 0.7+0.02 µm. After 12 hours incubation with cisplatin, the area 
occupied by lipid droplets in each cell increased significantly to 31.1+2.4% (p<0.05) and 
the mean diameter of lipid bodies reached 0.9+0.03 µm (p<0.001). Within 24 hours 
exposure the occupied area increased to 33.2+3.3% (p<0.05) and the diameter of the lipid 
droplets increased to 0.9+0.032 µm (p<0.001, compared to untreated cells).  
 
 
 
 
 
Figure 4.1.1. Nile red and DAPI images of cisplatin exposed cells for various times of 12, 24, 48 or 72 hrs. Cells were stained with Nile 
red and DAPI and images were captured by a Nikon E600 microscope coupled to a SPOT RT KE colour 3 shot CCD camera. Gray scale 
images were acquired and then images were psudocoloured red and blue to represent Nile red and DAPI, respectively. Coloured Nile red 
and DAPI images were then merged (The scale bars represent 20 micrometers).
 
 
 
 
Figure 4.1.2. Representative images of mitotic, viable, apoptotic and necrotic cells detected by Nile red and DAPI co-staining (The scale 
bars represent 5 micrometers).
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Figure 4.2. Mean percentage of cell area covered by lipid droplets in untreated and 
cisplatin treated samples (12, 24, 48, or 72 hrs) (*p<0.05, **p<0.001; the error bars are 
SEM). 
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Figure 4.3. Lipid droplet diameter of untreated and cisplatin exposed cells (12, 24, 48 or 
72 hrs). The results are presented as micrometer (µm) (*p<0.05, **p<0.001; the error bars 
are SEM). 
 
 
 
 
 
118 
 
Staining the cells with DAPI revealed small percentages of 9, 10, and 22% dead cells 
(apoptotic and necrotic cells)  in samples incubated with cisplatin for short times of 12, 
24, and 48 hours, respectively (figure 4. 4). The combination of Nile red and DAPI 
revealed that the increase in lipid droplets and their size at earlier exposure times of 12, 
24, 48 hours is detectable in cells that are morphologically viable and do not represent 
any characteristics of apoptosis or necrosis. The percentages of apoptotic and necrotic 
cells are in agreement with those determined by molecular studies of chapter 3. 
Therefore, alterations in lipid droplets at 12, 24, and 48 hours occur in growth arrested 
cells. At later stages of treatment, after 72 hours, the number of dead cells increased 
significantly to almost 53% (p<0.001). Higher number of apoptotic and necrotic cells at 
this time point were associated with 3.5 fold significant increase in lipid droplet area 
and almost 2 fold increase in their diameter reaching 1.2+0.04 µm (p<0.001).
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Figure 4.4. Percentages of dead cells revealed by DAPI staining in untreated and cisplatin 
exposed samples of different time points of 12, 24, 48 or 72 hrs (the sum of apoptotic and 
necrotic cells ♦, apoptotic ■, and necrotic ▲ cells ) (*p<0.05, **p<0.001; the error bars 
represent SEM). 
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4.3.2. Transmission Electron Microscopy Images  
Ultrastructural characteristics of untreated and 24 hours cisplatin exposed cells were 
studied and compared in more detail with TEM. In untreated samples, the cells represented 
viable features. They contained intact nuclei with peripheral chromatin, well developed 
endoplasmic reticulum (ER) and mitochondria were also detected. There were few lipid 
droplets present in the cell cytoplasm. Most of the treated cells contained features 
associated with viability such as peripheral chromatin in the nucleus as in untreated cells. 
However, increasing numbers of vacuoles were also detected in the images. The amount of 
cytoplasmic lipid droplets increased in cells with viable morphology.  Apoptotic cells were 
also present in the treated samples characterised by condensed and fragmented chromatin 
in the nuclei. Mitochondria and ER in these cells appeared swollen. Higher numbers of 
lipid droplets were also detected in the cytoplasm of the apoptotic cells (figure 4.5). 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.5. TEM images of control and 24 hrs cisplatin treated cells (LD- lipid droplets; SM- swollen mitochondria; V- vacuoles; IM- 
intact mitochondria).
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4.3.3.
 1
H HR-MAS NMR Visible Lipid Alterations 
The TARQUIN algorithm was used to assign and quantitate 
1
H HR-MAS NMR visible 
lipids. 
1
H HR-MAS NMR spectra for different cisplatin exposure times are presented in 
figure 4.6. 
 
 
 
Figure 4.6. 
1
H HR-MAS NMR spectra of untreated and cisplatin exposed cells of various 
time points of 12, 24, 48, or 72 hrs (Lipid signals labelled on the control spectrum are 
as follows: 1- 0.89  ppm, 2- 1.3 ppm, 3- 1.58 ppm, 4- 2.02 ppm, 5- 2.2 ppm, 6- 2.8 ppm, 7- 
5.4 ppm). 
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The quantities of lipids were calculated relative to the sum of macromolecule signals at 
0.94, 1.68, and 3.00 ppm as described in chapter 2, section 2.4.4. Relative quantities of 
mobile lipids at different cisplatin exposure times are given in table 4.1.  
 
 
 
Chemical shift  
(ppm) 
Untreated 
cells 
Cisplatin treated cells for different time intervals 
12h 24h 48h 72h 
Saturated 
and 
unsaturated 
Fatty acids 
0.89 
-CH3 
0.254+0.055 0.710+0.093* 1.015+0.197* 1.161+0.078** 1.632+0.330* 
 
1.3 
-CH2-CH2-CH2- 
1.042+0.095 2.959+0.269* 3.790+0.434* 3.896+0.330* 7.034+1.624* 
 
1.58 
-CH2-CH2-C=O 
0.020+0.007 0.159+0.011** 0.225+0.040* 0.215+0.033* 0.487+0.136* 
 
2.2 
-CH2-CH2-C=O 
0.308+0.047 0.629+0.064* 0.782+0.110* 0.803+0.050** 1.102+0.218* 
Unsaturated 
fatty acids 
 
2.02 
-CH2-CH2-CH= 
0.504+0.057 0.873+0.091* 1.061+0.162* 1.185+0.036** 1.650+0.254* 
 
2.8 
=CH-CH2-CH= 
0.056+0.021 0.143+0.022* 0.329+0.043* 0.449+0.024** 0.486+0.132* 
 
5.4 
=CH 
0.118+0.016 0.322+0.036* 0.584+0.101* 0.693+0.034** 1.003+0.237* 
 
  
Table 4.1. Quantities of 
1
H HR-MAS NMR visible lipids related to the sum of 
macromolecule signals at 0.94, 1.68, and 3.00 ppm in untreated and cisplatin exposed cells 
for different times (12, 24, 48, or 72 hrs). Three samples at each time point were analysed. 
The results are presented as mean+SD (*p<0.05, **p<0.001, compared to untreated 
samples).  
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Peaks at chemical shifts of 0.89, 1.3, 1.58, and 2.2 ppm represent methyl and methylene 
moieties which arise from saturated and unsaturated fatty acids. After drug exposure the 
relative concentration of all these peaks increased in intensity and continued to do so as the 
duration of drug exposure increased. After 12 hours cisplatin exposure, significant 
increases had occurred in all peaks. By 72 hours exposure to the drug, the lipid signals at 
0.89, 1.3, 1.58, and 2.2 ppm showed 6, 7, 24 and 4 fold increases in intensity compared 
with untreated samples (p<0.05).  
Peaks at 2.02, 2.8, and 5.4 ppm arise from unsaturated fatty acids. The relative 
concentration of these peaks also increased in intensity after drug exposure and continued 
to increase with longer cisplatin exposure times. After 72 hours cisplatin exposure, the 
relative concentration of lipid signals at 2.02, 2.8 and 5.4 ppm increased to approximately 
3, 9, and 8 fold, respectively, compared with untreated cells (p<0.05).  
To investigate the alterations in fatty acid chain length, the ratio of the signals -CH2-CH2-
CH2-/-CH3 were calculated (figure 4.7). The ratio of the signals 1.3/0.89 ppm remained 
unchanged, showing that the mean chain length of the fatty acids was not altered. 
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Figure 4.7. Ratio of the signals -CH2-CH2-CH2-/-CH3 did not alter with longer exposure to 
cisplatin showing that the mean chain length remains unchanged.  
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4.4. Discussion  
It was established in chapter 3 that the 
1
H HR-MAS NMR metabolites alter in response to 
cisplatin exposure of rat glioma BT4C cells undergoing cell cycle arrest. In this chapter 
1
H 
HR-MAS NMR visible mobile lipid alterations were investigated in these cells and it was 
determined that an increase in lipid signals is associated with accumulation of cytoplasmic 
lipid droplets in morphologically viable cells prior to appearance of cell death indicators.  
Nile red staining and subsequent image analysis revealed that an increase in both neutral 
lipid droplet amount and size within the cytoplasm was the likely source of 
1
H HR-MAS 
NMR visible lipid accumulation. Combining Nile red and DAPI provided further evidence 
to the trypan blue and H&E findings described in chapter 3, that after 12, 24, 48 hours 
treatment the number of apoptotic and necrotic cells are low and the majority of cells are 
morphologically viable. At these time points, a significant increase in 
1
H HR-MAS NMR 
visible lipids, lipid droplets and their size was detected indicating that the increase in 
1
H 
HR-MAS NMR visible lipids is due to lipid accumulation in cells which do not have 
morphological features of cell death. TEM images of cells treated for 24 hours confirmed 
that an increase in lipid droplets occurred in cells that contained homogenous chromatin; 
the characteristic feature of the nucleus in viable cells.  
The use of the TARQUIN algorithm to separate fatty acids from macromolecular signals in 
the 
1
H HR-MAS NMR spectra allowed a more detailed quantitation of the 
1
H HR-MAS 
NMR lipid signals and this data can be used to explore the composition of the detected 
fatty acid pool. Increases in the fatty acid signals at 0.89, 1.3, 1.58, and 2.2 ppm with 
longer exposure to cisplatin demonstrated accumulation of -CH3, -CH2-CH2-CH2- ,-CH2-
CH2-C=O, and -CH2-CH2-C=O moieties, respectively, arising from saturated or 
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unsaturated fatty acid chains. Contrary to previous studies (55), the ratio of the signals -
CH2-CH2-CH2-/-CH3 did not alter during treatment implying that there is not a substantial 
change in the mean chain length of the fatty acids. The difference between this finding and 
that of previous studies may be explained by the component which arises from the 
macromolecular signals since the ratio of the combined fatty acid and macromolecular 
signals 1.3 ppm/0.9 ppm does increase with treatment in these cells. There is a far greater 
contribution from macromolecules to the feature around 0.9 ppm than the one at 1.3 ppm 
accounting for the difference. The confounding influence of the macromolecular 
components around 0.9 ppm and 1.3 ppm implies that the use of these peaks in vivo as a 
marker of treatment response is likely to be tumour dependent. 
Unsaturated fatty acid signals were detected at 2.02 (-CH2-CH2-CH=), 2.8 (=CH-CH2-
CH=), and 5.4 ppm (=CH). In the control samples, the peak at 2.8 ppm is not readily 
detectable implying that the small amounts of unsaturated fatty acids present do not 
contain the polyunsaturated =CH-CH2-CH=, moiety. Increases in all the unsaturated fatty 
acid signals were seen after treatment and the ratio of the 
1
H HR-MAS NMR signals at 5.4 
ppm/2.8 ppm is close to 2 implying that almost all the unsaturated fatty acids are 
polyunsaturated and contain a moiety -CH=CH-CH2-CH=CH-. Given this finding, if we 
assume that each fatty acid has one –CH3 group, relative amounts of saturated and 
unsaturated fatty acid can be estimated. The ratio of the resonances at 0.89 ppm/2.8 ppm is 
approximately 3 in the treated samples, allowing for proton number, the ratio of the groups 
–CH3/=CH-CH2-CH= is approximately 2 implying that half of the fatty acids in the treated 
samples are saturated and the other half are polyunsaturated.  
Accumulation of lipids has been detected to occur in the pre-apoptosis phase (44) when 
lipid synthesis and turnover is taking place (141) and during growth arrest (43, 49, 79, 
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140).  In the study conducted by Hakumaki et al., an increase in polyunsaturated fatty acids 
was detected after GCV treatment of herpes simplex thymidine kinase transfected BT4C 
glioma cells and the potential of lipid accumulation as a marker of growth arrest and 
tumour response to therapy was demonstrated (50). This study on BT4C cell line confirms 
that such increases in 
1
H HR-MAS NMR lipid signals can arise from cytoplasmic lipid 
droplets in the cell cycle arrested cells. 
High phospholipid and PtCho turnover has been associated with the G1 stage of the cell 
growth cycle (141) and the level of phospholipid breakdown is high in this stage (142). 
This may explain the accumulation of lipids in cisplatin treated BT4C cells arrested in G1 
phase of the cell cycle. However, lipid accumulation was not correlated with growth arrest 
in Jurkat T-lymphoblasts (44) and transformed murine fibroblast (143). The detected 
accumulation of lipids was associated with lower proliferation rate (43, 143) and was 
suggested to provide useful information on tumour proliferation status in vivo (43). Holmes 
et al. detected lipid accumulation in stimulated lymphocytes but reducing the proliferation 
rate by cell cycle blockers did not alter the lipid profile (144). Furthermore Delikatny et al. 
did not detect changes in lipid signals of untreated and partially synchronised human 
glioma cells accumulated in S-G2/M but detected lipid accumulation in cells exposed to a 
cell cycle blocker prior to accumulation in G2/M phase. They associated identified lipid 
alterations to drug-cell interactions (78).  
Accumulation of lipids occurs under different circumstances. Increase in lipids has been 
detected in growth arrested (143), drug treated (145, 146), transformed and activated cells 
(144, 147-154). Delikatny et al. suggested that lipids develop in response to stress caused 
on the cells. They further suggested that the detected alterations occurring in response to a 
variety of conditions and treatments may indicate that a common pathway involving 
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phospholipid metabolism is effected. They proposed if this reaction is general it can be 
used to investigate cellular response to drugs in vivo and in vitro (78).   
Cyclin dependent protein kinase activity during cell cycle arrest/apoptosis indirectly effects 
cytidyltransferase and phosphorylation of this enzyme inhibits PtCho production (22, 141). 
PtdCho is the most abundant form of membrane phospholipid and is a precursor of two 
other dominant membrane phospholipids, phosphoethanolamine and sphingomyelin (141). 
Subsequently cell membrane synthesis and usage of compounds in the assembly of cell 
membranes is affected by reduced levels of PtdCho production (21). Activation of 
phospholipase A1, A2, and lysophospholipase have also been suggested as important 
contributors resulting in release of GPC (22, 78) and production of fatty acids (figure 4.8). 
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Figure 4.8. Phospholipid metabolism. Phospholipase A2 and lysophospholipase activity 
result in production of GPC and fatty acids. Fatty acids can be used in production of 
phospholipids and triglycerides. 
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Fatty acids can be re-esterified into phospholipids or used with diacylglycerol to produce 
TGs (48). This causes accumulation of CDP- choline and TG (65, 155) and results in 
formation of neutral lipid vesicles. The degraded phospholipid compounds such as choline 
and PC at cell membrane level are transferred freely to the ER for production of PtdCho 
(156). Diacylglycerol and fatty acids at cell membrane level are actively transported 
between membranes and the ER. This transport system is in the form of lipid droplets or 
bodies (156) containing neutral lipids such as TGs and cholesterol esters. In addition, lipid 
droplets may have proteins and enzymes for lipid metabolism and storage (45). 
Transformation of diacylglycerol to triacylglycerol (156), and providing compounds for 
other subcellular structures (45) has been related to the enzymes detected in the structure of 
these lipid droplets. Also it has been suggested that TG accumulation is an attempt to 
protect the cell from toxic effects of fatty acids and/or the activated derivatives (48). This 
may explain accumulation of lipids under various conditions causing stress. 
Transport of lipid bodies (156) and their NMR visibility have been associated with the cell 
cytoskeleton (22). Lipids are more mobile in vesicles than in membranes (21) and this 
together with an increase in number and size of lipid droplets amplifies their NMR 
visibility (156). 
Various other sources have been suggested and explored as reasons for the detected lipid 
accumulation.  Increase in de novo synthesis of fatty acids, decrease in β-oxidation of fatty 
acids (47, 48), excess release of fatty acids from intracellular storage (22), and/or increased 
uptake of lipids from exogenous sources such as serum are a few suggested reasons behind 
lipid accumulation (47, 48). In addition, energy status of the cell (22) and decrease or loss 
of mitochondrial membrane electrochemical potential during pre-apoptotic stages results in 
increased mitochondrial membrane permeability and influences the production of lipid 
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droplets by conversion of citrate to cholesterol and fatty acids (44) and at late stages of 
apoptosis breakdown of mitochondrial membrane by lysosomal enzymes may influence the 
level of fatty acids, glycerol and phosphodiesers (47).  
According to the proposal by Quintero et al. in normal conditions the lipid droplets are 
small and therefore are not NMR visible. However in this work the lipid droplets in 
untreated glioma cells were detectable by fluorescence microscopy and lipid resonances 
were prominent in the 
1
H HR-MAS NMR spectra which may indicate that the lipid 
droplets are bigger in the BT4C cell line than in C6 glioma cells, tested by Quintero et al. 
(156). This possibility may arise from the high concentration of TG in BT4C cells, as 
demonstrated in previous studies by biochemical assays (50).  
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4.5. Conclusions  
In this chapter, 
1
H HR-MAS NMR detected increases in saturated and unsaturated fatty 
acids in growth arrested BT4C glioma cells during exposure to cisplatin. Half of the fatty 
acids in these cells were saturated and the other half unsaturated. Further investigation 
revealed that the majority of unsaturated fatty acids were polyunsaturated and contain the 
moiety –CH=CH-CH2-CH=CH-. Furthermore, the unchanged ratio of CH2/CH3 indicates 
constant fatty acid chain length hence the detected increase in this ratio in previous reports 
are likely due to high macromolecule contribution to the 0.9 ppm signal. 
The 
1
H HR-MAS NMR lipid levels detected in BT4C cells were associated with an 
increase in the diameter and the amount of cytoplasmic lipid droplet. Direct analysis using 
DAPI and Nile red co-staining techniques confirmed that lipid accumulation occurred in 
cells which were morphologically viable and growth arrested. Comparison with molecular 
studies presented in chapter 3 indicated that these cells did not show early markers of 
apoptosis. Ultra-structural studies using TEM further confirmed that lipid droplets were 
present in morphologically viable cells. 
The findings described in this chapter and the results of other researchers indicate that 
lipids accumulate under various conditions and the detected increase in neutral lipids is a 
common feature of the stressed cells. Therefore NMR lipid accumulation shows potential 
as a general marker of cell stress and in particular treatment response. Their accumulation 
in malignant tumour cells treated with a cytostatic agent prior to the emergence of early 
indicators of cell death is particularly attractive for a non-invasive biomarker of treatment 
monitoring.  
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In the next chapter, necrosis is induced by starvation in glioma BT4C cells and 
1
H HR-
MAS NMR metabolite and lipid alterations are investigated in these cells. The results are 
compared with the data from cells exposed to cisplatin to investigate the common markers 
of cell stress and to further examine the potential of lipids as a general marker of stressed 
cells. In addition, the comparison of cisplatin and cell starvation allows identification of 
alterations specifically occurring in growth arrested cells or necrotic cells. 
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CHAPTER 5 
1
H HR-MAS NMR METABOLITE AND LIPID 
ALTERATIONS 
OF STARVATION INDUCED NECROSIS IN 
RAT BT4C CELLS 
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5.1. Introduction 
The ability to continue proliferating and developing resistance to apoptosis is one of the 
characteristics of tumour cells. Cancer biologists have begun to consider the application of 
necrosis-inducing methods for effective tumour therapy (9). Currently, various techniques 
including photodynamic treatment and alkylating DNA-damaging agents and a number of 
compounds such as lapachone, apoptolidin, and honokil have been reported to cause 
necrosis in tumour cells (157-160).  
Cellular stress caused by nutrient deprivation, results in ATP depletion and continued lack 
of nutrients and/or growth factors in culture results in necrosis (9, 161). Therefore, in this 
chapter, substrate starvation of BT4C cells is used as a model of cell necrosis and 
1
H HR-
MAS NMR lipid and metabolite alterations are investigated in order to identify biomarkers 
of this type of cell death.  
In chapter 4, an increase in saturated and polyunsaturated fatty acids was detected in 
response to cisplatin exposure and in growth arrested BT4C cells prior to apoptosis. 
Delikatny et al. suggested that lipids develop in response to stress caused in cells. They 
further suggested that the detected alterations may occur in response to a variety of 
conditions and treatments. They proposed that, if this reaction is general, it can be used to 
investigate cellular response to drugs in vivo and in vitro (78). To further investigate the 
potential of lipid alterations as markers of cell stress, in this chapter, 
1
H HR- MAS NMR 
lipid changes caused by necrosis due to starvation in BT4C cells is examined.  
Furthermore, an increase in lactate and GPC and a decrease in alanine, glycine, glutamate, 
succinate, and taurine was detected in cisplatin exposed BT4C cells (chapter 3). In this 
chapter relative metabolite alterations of BT4C cells are further investigated in response to 
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necrosis induced by starvation and the 
1
H HR-MAS NMR metabolite changes occurring 
during cell growth arrest and necrosis are compared in order to identify potential 
biomarkers of cell stress and markers distinguishing cytostasis and necrosis. 
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5.2. Methods 
Rat BT4C glioma cells were starved by maintaining them in PBS for various time intervals 
of 4, 6, 12, 18, or 24 hours. Viability of starved cells was investigated by trypan blue dye 
and the percentages of viable and necrotic cells were determined by H&E and DAPI 
staining based on morphological characteristics of cell nuclei. To further investigate the 
morphological alterations of cells due to starvation, TEM images were captured. 
1
H HR-
MAS NMR was performed in order to determine the lipid and metabolite profiles and their 
alterations in starved cells at various examined times. PCA was carried out on the 
metabolite data to identify alterations in metabolites in response to starvation and with 
longer substrate deprivation. The source of 
1
H HR-MAS NMR visible lipids was 
investigated by Nile red staining and ImageJ software was used to determine the 
association of 
1
H HR-MAS NMR lipid alterations with size and diameter of cytoplasmic 
lipid droplets. Finally to identify similarities and differences in the metabolite alterations of 
cisplatin exposed and starved BT4C cells, PCA was performed on the 
1
H HR-MAS NMR 
metabolite data set of both conditions. In each assay 3 independently prepared samples 
were tested for the time intervals examined (figure 5.1). 
 
 
 
 
Figure 5.1. Flow chart of the methods used in chapter 5. 
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5.3. Results 
5.3.1. Trypan Blue and Haematoxylin and Eosin Staining 
Trypan blue and H&E staining were carried out to determine the percentages of viable and 
necrotic cells in control and PBS maintained cells at various time points (4, 6, 12, 18, and 
24 hours). The viability status of 500 random cells was examined in each of the 3 
independent samples prepared for each time point. These techniques detected an increase 
in the number of necrotic cells by longer medium deprivation.  
Necrotic cells are unable to prevent trypan blue dye from entering and therefore are stained 
blue. The percentage of necrotic cells stained with this dye increased significantly from 
5.5+2.5% in control samples to 19.8+3.0% in 6 hours substrate deprived cells. The 
percentage of necrotic cells continued to increase significantly in samples deprived of 
substrates for longer, reaching 39.0+1.0%  and 59.3+6.3% after 18 and 24 hours starvation, 
respectively (p<0.001) (Figure 5.2).  
The number of H&E stained cells containing diffused chromatin and red-purple cytoplasm 
indicating necrotic cells increased in samples with longer incubation in PBS, further 
confirming the results of trypan blue staining (figure 5.2 and 5.3).  
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Figure 5.2. The percentages of necrotic cells detected by different methods of staining, 
trypan blue (♦), H&E (■), and DAPI (▲). The error bars are SEM. (*p<0.05, **p<0.001). 
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Figure 5.3. Images of control and starved cells after various time intervals (4, 6, 12, 18 or 
24 hrs), stained with H&E. The arrows are pointing to necrotic cells and the scale bars 
represent 20 micrometers.  
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The percentage of necrotic cells detected in H&E stained control samples were 5.9+1.6%. 
This percentage significantly increased to 20.9+2.4% in the cells deprived of substrates for 
4 hours (p<0.05) and continued to elevate significantly to 37.1+4.5% (p<0.05) and 
58.5+1.4% (p<0.001) after 12 and 24 hours of cell maintenance in PBS, respectively 
(figure 5.2). 
 
5.3.2. Nile red and DAPI staining    
PBS exposed cells were co-stained with Nile red and DAPI as described in chapter 2. Nile 
red was used to investigate the presence of lipid droplets in PBS exposed cells and to 
identify any alterations in the amount and diameter of these lipid bodies with longer 
substrate deprivation ImageJ software was used. DAPI was used in order to detect the 
viability status of the starved cells and to determine the method of cell death in these cells. 
For each time interval, 500 randomly chosen cells from each of the 3 prepared samples 
were measured.    
Nile red revealed the presence of lipid droplets in the cytoplasm of control and starved 
cells (figure 5.4). The diameter and the area of the cells covered by lipid bodies increased 
in stressed or early stage necrotic cells with longer maintenance in PBS (figures 5.5 and 
5.6).  Morphological characteristics of DAPI stained nuclei of PBS exposed cells revealed 
that necrosis is the main type of cell death in these samples and the number of necrotic 
cells increased with longer substrate deprivation (figure 5.4). 
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Figure 5.4. Nile red and DAPI images of starved cells. Control and starved cells for 
various times of 4, 6, 12, 18 or 24 hrs were stained with Nile red and DAPI. A Nikon E600 
microscope coupled to a SPOT RT KE colour 3 shot CCD camera was used to visualise 
and capture gray scale images. The images were merged after they were pseudocoloured 
red and blue to represent Nile red and DAPI, respectively (The scale bars represent 20 
micrometer). 
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The percentage of the cell area covered by lipid droplets showed an increasing trend by 
longer substrate deprivation. The lipid droplet area elevated significantly from 22.2+3.6% 
in control samples to 36.5+2.9% (p<0.05) and 38.9+3.03% (p<0.05) in samples incubated 
in PBS for 18 and 24 hours, respectively (figure 5.5).  
 
 
 
Figure 5.5. The mean percentages of cell area covered by lipid droplets in starved cells. 
The error bars are SEM (*p<0.05). 
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The lipid droplet diameter increased significantly (p<0.05) from 0.7+0.02 µm in control 
samples to 1.01+0.03 µm and 1.07+0.02 µm after 4 and 6 hours of starvation, respectively. 
The lipid droplet diameter continued to increase significantly (p<0.001) reaching 1.1+0.02 
µm and 1.2+0.04 µm after 18 and 24 hours incubation in PBS, respectively (figure 5.6). 
 
 
 
 
Figure 5.6. The diameter of cytoplasmic lipid droplets of starved cells. The error bars are 
SEM (*p<0.05, **p<0.001). 
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Viable and necrotic cells were distinguished from each other by morphological 
characteristics of their nuclei after DAPI staining. The percentage of necrotic cells detected 
by DAPI staining increased significantly (p<0.05) to 12.4+1.2%  after 6 hours medium 
deprivation and continued to increase reaching 30.1+4.3% and 30.5+5.7% after 18 and 24 
hours maintenance in PBS, respectively (p<0.001) (figure 5.2). 
Distinguishing stressed, viable cells from cells at early stages of necrosis was difficult due 
to the similarities between their nuclei features. Consequently the percentages of necrotic 
cells were underestimated. This emphasised that the results of other assays such as trypan 
blue or H&E are more reliable.  
 
5.3.3. Transmission Electron Microscopy Images  
The ultrastructural characteristics of substrate deprived cells at various time intervals of 6, 
12 or 24 hours were investigated with TEM. The cells maintained in PBS contained 
swollen mitochondria with condensed matrix. In some mitochondria, the cristae were lost 
or pushed to the sides forming ring or doughnut like structures. A few autophagic vacuoles 
and myelinoid bodies were detected in some cells. Lipid droplets were also detected in the 
cytoplasm of these cells. In some cells the extent of the damage to mitochondria was very 
severe and a double membrane ghost was seen.  Cell membrane rupture and debris were 
detected confirming the presence of necrosis in these samples (figure 5.7). 
 
 
 
 
Figure 5.7. TEM images of control and starved cells after 6, 12, and 24 hrs (LD- lipid droplets; A- autophagic bodies; SM- swollen 
mitochondria;  M- myelinoid bodies; V- vacuoles; IM- intact mitochondria).
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5.3.4.
 1
H HR-MAS NMR alterations 
The rat glioblastoma BT4C cells were harvested after 4, 6, 12, 18, and 24 hours of 
incubation in PBS. 
1
H HR-MAS NMR was performed on the prepared samples of each 
time point as described previously in chapter 2. The spectra are presented in figures 5.8 
and 5.9. The lipid, metabolite, and macromolecule signals were assigned and quantitated 
using the TARQUIN algorithm. The same methods used to measure relative levels of lipids 
and metabolites in cisplatin exposed BT4C cells (described in chapter 2) were applied here 
to determine relative concentrations of lipids and metabolites in BT4C cells incubated in 
substrate free medium. 
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Figure 5.8. 
1
H HR-MAS NMR spectra of BT4C cells following substrate starvation. (A) 
0.5 to 4.5 ppm region. Metabolites labelled are as follows:  1- lactate, 2-alanine, 3- 
glutamate, 4- succinate, 5- glutamine and aspartate, 6- creatine, 7- choline, 8- GPC and PC, 
9- taurine, 10- scyllo-inositol, 11- glycine, 12- myo-inositol, 13- guanidioacetate.  
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Figure 5.9. Choline containing region. metabolites labelled on the control spectrum are as 
follows: 1- choline, 2- phosphocholine, 3- glycerophosphocholine, 4- taurine, 5- 
phosphatidylcholine 6- glycine. 
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5.3.4.1.
 1
H HR-MAS NMR Visible Lipid Alterations 
The sum of macromolecule signals at 0.94, 1.68, and 3.00 ppm were used to calculate 
relative quantities of lipid signals (table 5.1). 
 
 
 
Chemical 
shift  
(ppm) 
 
Untreated 
cells 
       Cells incubated with PBS for various time intervals 
4h 6h 12h 18h 24h 
Saturated 
and 
unsaturated 
Fatty acids 
0.89 0.254+0.055 0.384+0.028* 0.480+0.023* 1.118+0.292* 1.200+0.209* 1.220+0.460* 
1.3 1.042+0.095 1.765+0.059** 2.032+0.091** 3.978+0.684* 4.597+0.677* 5.113+1.804* 
1.58 0.020+0.007 0.108+0.004** 0.130+0.011** 0.301+0.033** 0.306+0.042* 0.416+0.186* 
2.2 0.308+0.047 0.346+0.022 0.384+0.004 0.690+0.130* 0.731+0.110* 0.791+0.281* 
Unsaturated 
fatty acids 
2.02 0.504+0.057 0.581+0.031 0.625+0.017 1.081+0.199* 1.131+0.153* 1.205+0.383* 
2.8 0.056+0.021 0.104+0.007* 1.163+0.008* 0.267+0.036* 0.366+0.107* 0.293+0.073* 
5.4 0.118+0.016 0.177+0.004* 0.213+0.005* 0.534+0.115* 0.651+0.146* 0.652+0.272* 
 
Table 5.1. Relative quantities of 
1
H HR MAS NMR visible lipids in control, and starved 
cells. Three samples at each condition were analysed. The results are presented as 
mean+SD (*p<0.05, **p<0.001, compared to untreated samples).    
 
 
Saturated and unsaturated moieties of fatty acids contributing to 0.89, 1.3, 1.58, and 2.2 
ppm signals and unsaturated fatty acid moieties represented by peaks at 2.02, 2.8, 5.4 ppm 
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increased following replacement of medium with PBS. The detected lipid signals 
continued to rise significantly by prolonging the incubation time in PBS.   
The signals at 0.89 and 1.3 ppm increased 5 fold (p<0.05) and the peak at 2.2 ppm elevated 
3 fold (p<0.05) after 24 hours PBS replacement. The signal at 1.58 ppm increased 15 fold 
after 12 hours PBS exposure and continued to elevate reaching 0.4+0.2 with a 21 fold 
increase after 24 hours (p<0.001 and p<0.05; respectively). The ratio of the signals 
1.3/0.89 arising from –CH2-CH2-CH2-/-CH3 moieties did not change indicating that the 
mean chain length of fatty acids did not alter by longer maintenance of the cells in PBS. 
After 12 hours PBS replacement, the lipid signals at 2.02 and 2.8 ppm increased to 
approximately 2 and 5 fold, respectively (p<0.05), and the intensity of the 5.4 ppm signal 
reached 0.6+0.1 after 18 hours PBS replacement with 6 fold increase compared with cells 
sustained in the substrate containing-medium (control samples) (p<0.05).  
Similar results to the cisplatin exposed cells were detected for the ratio of 5.4 ppm/2.8 ppm 
signals. This ratio is approximately 2 indicating that almost all the unsaturated fatty acids 
are polyunsaturated containing –CH=CH-CH2-CH=CH- moiety. The ratio of 0.89 ppm/2.8 
ppm (-CH3/=CH-CH2-CH=) was around 4 in PBS exposed cells. Allowing for the proton 
number, approximately a third of the fatty acids are polyunsaturated and the rest are 
saturated. 
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5.3.4.2.
 1
H HR-MAS NMR Metabolite Alterations 
Using the TARQUIN algorithm, several metabolites were identified and quantitated. The 
relative concentration of each of the metabolites was calculated relative to the sum of all 
the identified metabolites (table 5.2) and the significant alterations in the pattern of the 
detected relative metabolites were determined compared to control samples (table 5.3).
 
 
 
 
 
 
 
 
 
 
 
 
Metabolites Untreated cells 4h 6h  124h  18h  24h  
Acetate 8.08E-04+7.04E-04 2.61E-04+4.47E-04 2.53E-04+4.39E-04 4.73E-04+8.19E-04 2.32E-04+4.03E-04 2.09E-04+3.62E-04 
Alanine 9.90E-02+4.30E-03 2.18E-02+3.21E-02 1.43E-02+3.44E-03 7.94E-03+2.92E-03 2.80E-03+6.83E-04 1.20E-02+2.07E-02 
Aspartate 4.58E-02+6.64E-03 4.33E-02+1.09E-02 4.85E-02+6.35E-03 6.32E-02+2.55E-03 4.69E-02+3.09E-02 4.15E-02+2.10E-02 
Choline 1.28E-02+3.09E-03 1.08E-02+8.36E-04 2.24E-02+6.35E-03 2.43E-02+1.20E-03 3.18E-02+8.30E-03 2.59E-02+6.86E-03 
Creatine 1.34E-02+3.87E-03 1.65E-02+2.42E-03 1.62E-02+4.94E-04 2.26E-02+1.23E-03 1.80E-02+4.91E-03 1.77E-02+5.22E-03 
Glutathione 7.01E-02+3.19E-02 6.31E-02+7.08E-03 5.23E-02+2.29E-03 4.58E-02+3.07E-03 2.61E-02+9.07E-03 3.55E-02+4.48E-03 
Glutamate 2.59E-01+2.91E-02 7.64E-02+6.02E-03 1.41E-02+1.19E-02 1.45E-03+1.28E-03 0.00E+00+0.00E+00 6.89E-03+6.26E-03 
Glutamine 2.06E-02+6.43E-03 1.18E-03+2.04E-03 5.48E-03+9.50E-03 0.00E+00+0.00E+00 0.00E+00+0.00E+00 5.52E-03+9.55E-03 
GPC 3.87E-02+2.11E-02 8.07E-02+8.80E-03 1.43E-01+1.70E-02 1.96E-01+1.86E-02 2.21E-01+4.08E-02 1.93E-01+4.75E-02 
Glycine 1.09E-01+2.15E-02 1.03E-01+6.55E-03 6.51E-02+8.05E-03 4.86E-02+5.45E-03 3.89E-02+2.35E-02 7.60E-02+2.84E-02 
Lactate 1.06E-01+3.00E-02 7.31E-02+9.92E-03 6.54E-02+5.72E-03 8.90E-02+2.28E-02 6.89E-02+4.75E-03 7.36E-02+8.03E-03 
Myo-Inositol 7.79E-03+1.13E-02 0.00E+00+0.00E+00 0.00E+00+0.00E+00 0.00E-00+0.00E+00 0.00E-00+0.00E+00 0.00E+00+0.00E+00 
PC 8.38E-02+7.63E-03 1.19E.01+1.63E-02 1.27E-01+5.67E-03 1.29E-01+1.01E-02 8.45E-02+1.61E-02 6.74E-02+5.21E-03 
PEth 0.00E+00+0.00E+00 0.00E+00+0.00E+00 0.00E+00+0.00E+00 0.00E+00+0.00E+00 0.00E+00+0.00E+00 0.00E+00+0.00E+00 
Scyllo-inositol 3.13E-03+1.38E-03 2.29E-03+9.86E-04 1.27E-03+5.02E-04 2.26E-03+4.60E-04 3.91E-04+6.77E-04 0.00E+00+0.00E+00 
Succinate 5.59E-03+2.60E-03 2.17E-03+1.03E-04 1.66E-03+6.96E-04 1.93E-04+1.68E-04 2.70E-04+2.59E-04 6.29E-04+2.37E-04 
Taurine 7.82E-02+1.93E-02 6.65E-02+6.53E-03 5.97E-02+6.41E-03 1.01E-01+1.56E-03 6.05E-02+9.96E-03 7.98E-02+2.09E-03 
Hypo-Taurine 2.40E-02+5.54E-03 2.65E-02+4.62E-03 2.69E-02+1.70E-03 2.81E-02+5.64E-04 2.47E-02+9.56E-03 3.16E-02+1.21E-02 
Guanidioacetate 4.05E-03+4.38E-03 2.70E-01+5.51E-02 3.11E-01+5.70E-02 2.13E-01+2.66E-03 3.55E-01+1.54E-01 3.06E-01+9.97E-02 
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Table 5.2. Relative concentration of 
1
H HR-MAS NMR detectable metabolites in control 
and starved cells. The results are presented as mean+SD. Three samples at each condition 
were analysed.   
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Table 5.3. 
1
H HR-MAS NMR alterations detected in the relative concentration of the 
metabolites during cell starvation. (↑) represents an increase in relative metabolite levels 
and (↓) represents a decrease in relative metabolite levels compared to control cells 
(*p<0.05, **p<0.001). 
 
The metabolite profile of BT4C cells incubated in PBS changed compared to cells 
incubated in culture medium and further alterations were detected in samples deprived for 
longer. An increase in GPC and a decrease in alanine, succinate, and glutamate were 
detected with longer starvation. PC levels increased up to 12 hours of substrate deprivation 
Metabolites 
 Starved cells 
 4h 6h 12h 18h 24h 
PC   *↑ **↑ **↑   
GPC    **↑ **↑ **↑ **↑ 
Choline      **↑  
Alanine   **↓ **↓ **↓ **↓ **↓ 
Scyllo-Inositol      *↓ *↓ 
Succinate   *↓ *↓ **↓ **↓ *↓ 
Glycine     *↓ *↓  
Glutamate   **↓ **↓ **↓ **↓ **↓ 
Glutathione      *↓  
Guanidioacetate   *↑ **↑ *↑ **↑ **↑ 
PC/GPC      *↓ *↓ 
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and alteration in the levels of aspartate, lactate, creatine, hypo-taurine, and taurine were not 
detected. In addition PEth and myo-inositol were not detectable in the samples. 
PCA was performed on the relative concentration of metabolites (figure 5.8). The first 
principal component is the main separation factor of the control and substrate starved cells 
(figure 5.10.A). This component accounts for approximately 42% of the variance. Starved 
cells are well separated from cells maintained in culture medium in this principal 
component. Cells incubated in medium are at the far left of the plot, occupying the 
negative scores and the positive scores are occupied by PBS maintained cells. Starved 
samples at various time intervals are close to each other on the PCA score plots. However, 
they are separated from each other, with the earlier time points skewed towards the 
negative scores and the longer incubation times occupying increasingly positive scores of 
the principal component 1 coefficient (figure 5.10.A). According to the principal 
component 1 loadings (figure 5.10.B) cell starvation lead to lower levels of succinate, 
glutamate, glutathione, glutamine, scyllo-inositol, acetate, and alanine and higher levels of 
GPC, creatine, and choline (figure 5.10.B). The PCA results confirm the findings of the 
one way- ANOVA tests.  
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Figure 5.10. PCA of 
1
H HR-MAS NMR metabolite profiles for substrate starved cells. (A) 
Scores plot, (B) Loadings for principal component 1, (C) Loadings for principal 
component 2.  
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5.3.5. Principal Component Analysis of Cisplatin Exposed and Substrate 
Deprived Metabolite Data of BT4C cells 
PCA was performed on the 
1
H HR-MAS NMR metabolite data of cisplatin exposed cells 
presented in chapter 3 and 
1
H HR-MAS NMR relative metabolite data of starved cells 
described in this chapter (figure 5.11). Analysis was performed on both sets of data to 
understand better the relative metabolite alterations due to necrosis and cell growth arrest 
prior to apoptosis in rat BT4C cells and to identify the similarities and differences between 
the metabolite alterations caused by these conditions. 
The scores plot for the PCA of the metabolite profiles is presented in Figure 5.11.A. Only 
nutrient starvation is associated with a change in the first principal component and this 
change occurs early in the time course. A decrease in the second principal component 
occurs during both cisplatin exposure and nutrient starvation. From the loadings plot for 
principal component 2 (Figures 5.11.C), both cisplatin exposure and cell starvation are 
associated with changes in many metabolites, the most prominent changes being decreases 
in glycine, succinate and glutamate with an increase in GPC. Alterations which were 
specific to early changes during nutrient starvation can be deduced from the loadings plot 
for principal component 1 (figure 5.11.B). Again, many metabolites contributed but the 
largest loadings were associated with decreases in glutamate and alanine. 
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Figure 5.11. PCA of 
1
H HR-MAS NMR metabolite profiles for cisplatin exposed and 
substrate starved cells (A) scores plot, (B) loadings for principal component 1, (C) loadings 
for principal component 2. 
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5.4. Discussion 
Microscopic analysis of various staining techniques including DAPI, trypan blue, and 
H&E revealed that with longer substrate deprivation the number of necrotic cells 
increased. Large vacuoles were identified by H&E staining in cells incubated with PBS. 
Further by using TEM necrosis was confirmed as the type of cell death and the presence of 
cytoplasmic vacuoles and swollen mitochondria was revealed in these cells. In addition, 
some of the cells contained autophagic and myelinoid bodies in their cytoplasm.   
Increases in the diameter and the cell area occupied by lipid droplets were observed in 
necrotic and viable, stressed cells. This implies that the cytoplasmic lipid droplets are the 
source of the detected increase in lipid signals by 
1
H HR-MAS NMR. Saturated and 
unsaturated moieties of fatty acids at 0.89, 1.3, 1.58, and 2.2 ppm and unsaturated fatty 
acids represented by peaks at 2.02, 2.8, 5.4 ppm increased with longer substrate 
deprivation.  
Increase in 
1
H HR-MAS NMR visible lipids in necrotic regions of tumours has been 
identified previously (42, 46, 110, 162). Mobile lipid signals were detected in vivo by 
1
H 
MRS in necrotic and perinecrotic regions of C6 rat brain glioma and they were associated 
with accumulation of lipid droplets (42, 46). Kuesel et al. also ascribed the increase in 
mobile lipid resonances detected by in vivo 
1
H MRS to the necrotic foci of several high 
grade astrocytomas (56). A correlation was also detected between lipid droplets and 
1
H 
MRS lipid signals in human brain tumour biopsy samples. The lipid droplets were detected 
in non-necrotic regions of grade II and III astrocytomas and in higher levels in necrotic 
regions of grade IV astrocytoma. It was suggested that lipid droplets in high grade 
astrocytoma accumulate during the transition from hypoxia to necrosis. This finding 
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indicated that lipid droplets are formed prior to necrosis (110). The presence of lipid 
droplets in viable, stressed BT4C cells in substrate deprived medium is in agreement with 
previous findings and demonstrates the formation of lipid droplets prior to necrosis. The 
detected alterations in 
1
H HR-MAS NMR visible lipids and the identified source of lipid 
increase in starved cells were similar to the results found in cisplatin exposed cells of 
various time points described in chapter 4. 
In addition to lipid alterations, relative concentrations of metabolites were altered with 
longer substrate deprivation. In these samples, an increase in choline and GPC and a 
decrease in the levels of alanine, glycine, glutamate, succinate, and scyllo-inositol were 
noticed. The detected levels of lactate, aspartate, creatine, taurine, and hypo-taurine did not 
alter during longer periods of substrate deprivation. In addition, PEth and myo-inositol 
were not detectable in the samples and PC levels were decreased after an initial increase up 
to 12 hours substrate deprivation.  
Necrosis cell death is a regulated event and consists of serial steps (9, 86, 87). 
Morphological characteristics are the best method to identify and distinguish necrosis from 
apoptosis cell death. Swelling of organelles such as mitochondria and loss of membrane 
integrity are associated with necrosis. In addition, necrosis does not require energy and the 
production of bioenergetic compounds are impaired in this process.  
Nutrient deprivation causes necrosis in cells by ensuring a drastic decrease in cellular 
energy. Impaired bioenergetic status causes decreased activity of ATP-dependent ion 
pumps situated in the cell membrane. Consequently ion homeostasis is altered affecting 
mitochondria and ATP production through oxidative phosphorylation (9). Cells try to 
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survive by autophagy and by consuming cell resources such as macromolecules (9, 161, 
163), however if the nutrients are not replaced cells progress to necrosis (161). 
Oxidative phosphorylation is a more efficient pathway of ATP production compared to 
glycolysis. However, ATP production via glycolysis occurs at a faster rate and it is the 
main source of energy production in tumour cells (122). The rate of glycolysis depends on 
glucose availability and lactate clearance (9). Therefore, absence of glucose in the medium 
causes a decrease in bioenergetic compounds in tumour cells. Reduced energy levels 
results in necrosis followed by impaired mitochondria and oxidative phosphorylation. As 
the BT4C cells were incubated in substrate free medium, amino acids such as alanine, 
glycine, and glutamate and the TCA cycle intermediates such as succinate and scyllo-
inositol may have entered pathways resulting in ATP generation in an attempt to survive. 
Hence, a decrease was detected in the relative level of these metabolites in starved BT4C 
cells (figure 5.12).   
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Figure 5.12. The relevant metabolite pathways in starved BT4C cells. In this diagram, the 
metabolites with red arrows altered significantly with longer substrate deprivation (Ala. 
alanine, Arg. Arginine, Asn. asparagine, Asp. aspartate, Cys. cysteine, Glu. glutamate, Gln. 
glutamine, Gly. glycine, His. histidine, Ile. isoleucine, Leu. leucine, Lys. lysine, Met. 
methionine, Phe. phenylalanine, Pro. proline, Ser. serine, Thr. threonine, Trp. tryptophan, 
Tyr. tyrosine, Val. Valine). 
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An increase in 
1
H HR-MAS NMR visible lipids and lipid droplets containing neutral lipids 
as well as elevated levels of GPC and PC indicate the possibility of phospholipid 
catabolism as the underlying mechanism of the detected alterations (78).  
An increase in MRS visible lipids was detected in human breast cell line HBL-100 treated 
with cationic lipophilic agents. In these necrotic cells, swollen mitochondria with 
disordered cristae and myelinoid bodies were identified. The degradation of damaged 
mitochondria by lysosomal enzymes was suggested as the reason behind the detected 
alterations (47). Lysosomal enzymes such as sphingomyelinase and phospholipase A1, A2, 
and C process phospholipids and produce fatty acids, glycerol, and phosphodiesters. Fatty 
acids and glycerol are exported from the lysosome and TGs are produced from the fatty 
acids (47, 164) (described in chapter 4). There is a possibility that in necrotic BT4C cells 
lysosomal enzymes catabolise PLs and degrade them to fatty acids, resulting in the 
detected increase in 
1
H HR-MAS NMR lipids and cytoplasmic lipid droplets. 
Furthermore, the detected increase in PC and GPC levels is in agreement with the 
suggested PL degradation mechanism and the previous findings associating an increase in 
membrane substrates with cell death (165).  
It has been suggested that phospholipase D (PLD) is specifically activated in response to 
TNF-induced necrosis vs. apoptosis resulting in production of choline. Mitochondrial 
damage during the necrosis process results in formation of reactive oxygen species and 
damage to the membrane by lipid peroxidation. PLD activity perhaps is a mechanism to 
repair the damage caused to the cell (166).   
The increase in PC levels up to 12 hours into substrate deprivation indicates activation of 
PLC and catabolism of membrane PtCho. It has been suggested that PLA2 is activated 
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during the late stages of necrosis (166).  Activation of PLC during early stages and PLA2 
during late stages of substrate deprivation would explain the high level of PC at early 
stages and an increase in GPC level at later stages of necrosis in BT4C cells.  
 
5.4.1. Cell Growth Arrest Leading to Apoptosis vs. Necrosis 
The current study shows that drug-induced cell growth arrest and starvation–induced 
necrotic cell death cause both common and distinct changes in cellular metabolites. Both 
challenges result in increases in GPC and decreases in alanine, glutamate, glycine and 
succinate. Decreases in amino acids such as alanine, glutamate, glycine and the TCA cycle 
intermediates, such as succinate, in growth arrested cells prior to apoptosis and in necrotic 
cells indicate a redirection of metabolites to energy production rather than consumption 
through synthesis pathways. Lactate and alanine can also be linked to energy metabolism 
and although there have been fewer reports related to the levels of succinate and glutamate, 
these are also closely involved with energy metabolism. The trend detected is similar under 
both conditions. However, the extent of the alterations caused by cell cycle arrest or 
necrosis differs. 
High levels of glycine, taurine and glutamate have all been seen in highly malignant 
tumours and have been proposed as biomarkers of malignancy (128). It is therefore of 
interest that relative levels of these metabolites decrease with drug response. The detected 
decrease in taurine levels in growth arrested cells (chapter 3) and the lack of significant 
taurine alterations in necrotic cell emphasises that this metabolite is not associated with all 
forms of cell stress or cell death and further investigation of its role in tumour cells is 
required.  
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Combined levels of GPC, PC and Choline are usually measured in in vivo 
1
H MRS due to 
the poor spectral resolution. The tCho level relative to the total metabolite concentration 
decreased with longer substrate deprivation indicating altered levels of metabolites 
contributing to tCho. However, tCho was not altered relative to the total metabolite 
concentration when the cells were treated with cisplatin. With significant alterations in the 
levels of PC and GPC in cisplatin treated cells, this work emphasises the risk of using a 
combined quantity for treatment monitoring when the components are affected differently 
by treatment. 
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5.5. Conclusion 
Increases in saturated and unsaturated fatty acids were detected in starved cells by 
1
H HR-
MAS NMR spectroscopy. Almost one third of the fatty acids detected were unsaturated, 
mainly polyunsaturated fatty acids. Investigations revealed that cytoplasmic lipid droplets 
are the source of lipid accumulation and the likely source of lipids detected by 
1
H HR-
MAS NMR. DAPI and Nile red co-staining revealed the presence of lipid droplets in early 
necrotic and viable, stressed cells, indicating the early formation of lipid droplets in 
stressed cells. Accumulation of 
1
H HR-MAS NMR lipids in stressed or necrotic cells 
provided further evidence on the potential of NMR lipids as markers of cell stress. 
Energy metabolism was affected in starved BT4C cells and decreased levels of amino 
acids such as glycine, glutamate, and alanine and the TCA cycle intermediates such as 
succinate were detected. Unlike growth arrested cells, taurine levels did not alter in 
necrotic BT4C cells, demonstrating the potential of taurine in distinguishing necrosis from 
cell cycle arrest. Both GPC and PC levels increased initially in starved BT4C cells. The 
contrast between the PC pattern of growth arrested cells and necrotic cells may represent 
different patterns of activity in phospholipase in response to the mode of cell death and the 
stimuli. 
Although the time–dependency and magnitude of the alterations were different in cisplatin 
exposed cells and starved cells, PCA revealed two patterns of metabolite changes, one 
which was common to both types of cell stress and another which was specific for necrosis 
induced by cell starvation.  Glycine, alanine and glutamate may provide new biomarkers of 
cell stress and cell death whilst taurine may distinguish between cytostasis and necrosis. 
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CHAPTER 6 
CONCLUSIONS 
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6.1. Summary and Conclusions 
Early detection of tumour therapy response is a powerful indicator of outcome and by 
identifying unsuccessful therapy at early stages of treatment alternative therapy can be 
selected and the patient‟s quality of life can be improved.  
Glioma is the most common form of primary brain tumour of the CNS in humans and has a 
poor prognosis. Identifying markers of treatment efficacy non-invasively may influence the 
clinical management of this tumour.  
 
In this work, rat BT4C cell line was used as a model for glioma and 
1
H HR-MAS NMR 
spectroscopy was used to identify metabolite and lipid alterations in response to cell cycle 
arrest or necrosis. 
Compared with in vivo MRS studies, in vitro experiments have better spectral resolution 
and have the advantage of revealing higher number of metabolites and lipids. In addition, 
in in vivo settings the surrounding tissue influences tumour metabolite and lipid profiles. In 
contrast, the experimental conditions can be more controlled in in vitro and the effects of 
various factors on lipid and metabolite profiles can be investigated.  
Using cells rather than extracts provides a closer system to in vivo models and enables 
study of lipids and metabolites simultaneously. In addition, by using whole cells minimum 
sample preparation on a small number of cells is required. During performance of MRS the 
cells remain viable for a period of time. This provides the opportunity to use the samples 
for further investigations. However, due to inhomogeneity of the cells MRS spectra may 
have poor resolution and low signal to noise ratio. During 
1
H HR-MAS NMR 
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spectroscopy, cells are spun at a specific angle. This reduces the effects of dicoupling and 
chemical shift anisotropy, resulting in improved spectral resolution from inhomogeneous 
samples within a short time.  
 
In chapter 3 trypan blue and H&E dyes were used and in chapter 4 cells were stained with  
DAPI to investigate viability of rat glioma BT4C cells exposed to 50 µM cisplatin after 
various times of 12, 24, 48, or 72 hours. In chapter 3, the occurrence of DNA fragments on 
gel electrophoresis were used to determine the presence of apoptosis in cisplatin exposed 
cells and flow cytometry of annexin V-FITC labelled and PI stained cells were used to 
determine the percentages of viable, necrotic, and apoptotic cells.  Further investigations 
using flow cytometry and PI dye were carried out to identify cell distribution in different 
stages of growth cycle.  
In chapter 4 TEM was used to further confirm the type of cell death in cisplatin exposed 
cells. Combination of Nile red and DAPI staining were used to investigate the presence of 
lipid droplets in the cytoplasm of viable, growth arrested cells.  
Finally, 
1
H HR-MAS NMR spectroscopy was performed on cisplatin exposed cells of 
various times to identify metabolite and lipid alterations in response to treatment. 
Metabolite changes were described in chapter 3 and lipid alterations were explained in 
chapter 4 (figure 3.1).   
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Morphological and molecular analysis showed that the majority of cisplatin exposed BT4C 
cells were viable and small numbers were undergoing apoptosis or necrosis and that the 
morphologically viable cells were growth arrested.  
1
H HR-MAS NMR revealed increased relative levels of saturated and unsaturated lipids in 
these cells with longer cisplatin exposure. Direct examination of these cells using Nile red 
and DAPI co-staining associated the detected 
1
H HR-MAS NMR lipid increase with the 
alterations in the amount and size of cytoplasmic lipid droplets in the cell cycle arrested 
cells. 
1
H HR-MAS NMR metabolite alterations revealed a decrease in relative levels of PC 
and an increase in relative concentrations of GPC by exposure to cisplatin and PC/GPC 
ratio reduced in these cells. A decrease in PC levels has been identified in response to 
chemotherapy and has been proposed as an early marker of treatment efficacy (63). The 
detected decrease in PC/GPC level is in agreement with previous findings of cell cycle 
arrest studies and may indicate growth arrest prior to apoptosis (50). The relative levels of 
glycine, glutamate, alanine and succinate decreased by longer cisplatin exposure. Reduced 
relative levels of these amino acids along with increased relative levels of lactate indicate 
altered energy metabolism pathways in cisplatin exposed cells and provide potential novel 
biomarkers for early treatment response in gliomas. 
 
In chapter 5 cell stress and necrosis was induced by maintaining the rat glioma BT4C cells 
in PBS for different time intervals of 4, 6, 12, 18, or 24 hours. Cell viability was examined 
using trypan blue dye and the percentages of necrotic and viable cells were identified by 
H&E and DAPI staining. TEM was used to confirm the viability status of PBS maintained 
cells and to study the ultrastructure of these cells. Nile red and DAPI dyes were used to 
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investigate the presence of lipid droplets in cytoplasm of stressed and necrotic cells (figure 
5.1). 
 
Morphological analysis of BT4C cells maintained in substrate free medium revealed the 
presence of stressed and necrotic cells. An increase in relative levels of saturated and 
unsaturated fatty acids was detected by 
1
H HR-MAS NMR. Nile red and DAPI co-staining 
associated this increase with the presence of cytoplasmic lipid droplets in viable, stressed 
cells and necrotic cells. 
1
H HR-MAS NMR metabolite investigations revealed an initial 
increase in PC and continual increase in GPC relative levels. In addition decreases in 
amino acids such as alanine, glycine, glutamate, and TCA cycle intermediates such as 
succinate were identified. 
1
H HR-MAS NMR lipid accumulation following induction of cytostasis or necrosis and the 
presence of associated cytoplasmic lipid droplets in stressed, growth arrested or necrotic 
cells shows that lipid accumulation is a general indicator of cell stress and occurs early in 
the process. Lipid accumulation and the presence of cytoplasmic lipid droplets in both 
conditions show that alterations in phospholipid metabolism are prominent in cell stress.  
 
The alterations in phospholipid metabolism pathway and the activity of phospholipase 
enzymes have been previously suggested to influence the levels of lipid droplets in stressed 
cells (78). Activation of phospholipases A1, A2, and lysophospholipase result in 
production of fatty acids (22, 78). The produced fatty acids can be re-esterified to generate 
phospholipids such as PtdCho or in the presence of DAG can produce TAG (48). DAG and 
fatty acids are actively transported between membranes in form of lipid droplets (156). In 
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growth arrested cells PhtCho is not used in membrane synthesis and it is degraded to 
choline and fatty acids. This results in accumulation of lipid droplets. During early stages 
of starvation induced necrosis, cell membranes and other cellular components are degraded 
in order to provide substrates for cell survival (161). 
 
Alterations in PC and GPC levels provide further evidence for altered phospholipid 
metabolism. The difference in the detected pattern of PC alterations in growth arrested or 
necrotic cells implies that there is not a single common mechanism for altered choline 
metabolism and that the activities of various phospholipase enzymes differ following 
initiation of cytostasis or necrosis.  For example phospholipase D activity has been 
detected in TNF-induced necrosis (166).   
 
The level of tCho remained constant by longer exposure to cisplatin. However, the 
individual metabolites contributing to tCho altered and the detected changes were different 
in cisplatin exposed and starved cells. In cisplatin exposed cells GPC relative levels 
decreased and PC relative levels increased by exposure to cisplatin and in starved cells the 
relative concentrations of PC and GPC increased. This further highlights the potential of 
the individual tCho metabolites as biomarkers of tumour response and emphasises the 
importance of separating these metabolites in vivo. 
 
A decrease in the levels of amino acids (alanine, glycine, glutamate) and TCA cycle 
intermediates (succinate) following induction of cell cycle arrest or necrosis indicates 
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alteration in the energy metabolism pathways. Increase in relative levels of lactate in 
growth arrested cells show that the effected pathways are different in necrotic and cell 
cycle arrested cells. Previous studies have shown an association between high levels of 
glycine, glutamate, taurine with malignancy (116, 128, 129). As the levels of alanine, 
glycine and taurine are high in malignant cells, decreased relative levels of these 
metabolites provide early biomarkers of cell stress and cell death. 
 
Taurine levels decreased in growth arrested cells and remained constant in necrotic cells. 
This shows that alterations in taurine levels are not representative of all types of cell stress 
or cell death. Perhaps release of taurine and other osmolytes in growth arrested cells prior 
to apoptosis are indicative of progression to apoptosis and cell shrinkage (138- 139). High 
levels of taurine in primitive neuroectodermal tumours with high proliferation levels were 
detected (137). Reduced taurine levels in growth arrested cells may have the potential to 
identify growth arrest prior to apoptosis and may have the potential to be used in 
distinguishing different types of cell death. 
 
A number of detected metabolite alterations were common in growth arrested cells and 
necrotic cells. An increase in saturated and unsaturated fatty acids, a decrease in amino 
acids and TCA cycle intermediates have been identified during cytostasis and cell death. 
Therefore, these metabolites may have the potential to be used as indicators of cell stress. 
A group of metabolites altered differently in growth arrested and necrotic cells. The 
changes in individual choline containing metabolites and taurine relative levels were 
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different in growth arrested cells prior to apoptosis and in necrotic cells and may have the 
potential to distinguish between cytostasis and necrosis. 
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6.2. Future Work 
The work carried out here investigated relative alterations of lipids and metabolites in one 
cell line and in response to cisplatin exposure or substrate deprivation. Future work on 
other cell lines using different stimuli is required to confirm the potential of the detected 
alterations as general markers of cell stress and to investigate their ability to distinguish 
cytostasis from necrosis.  
Different animal and human glioma cell lines are required to be examined in order to 
confirm the changes detected previously in response to treatment in gliomas. Perhaps 
examination of other cell types would provide general markers of cell stress and cytostasis. 
Further examining the metabolite profiles of cell extracts would confirm the spectra 
achieved from MRS of the whole cells and may provide further information.   
Although there are advantages in working with cell lines, a monolayer culture does not 
reflect all properties of tumours and as the ultimate goal is to use the detected metabolite 
alterations as markers of treatment efficacy in clinical settings, in vivo applicability of 
these in vitro biomarkers require investigations. The next step would be to examine animal 
models. In addition more information can be gained from comparing the MRS spectra of 
patients at diagnosis and throughout treatment. 
Cell death mainly apoptosis and necrosis can be induced in cells via different stimuli. 
Metabolite profiling after induction of cell death by different methods of treatment such as 
chemotherapy, photodynamic or gene therapy may provide useful information and assist in 
identifying general markers of treatment efficacy. The biochemical pathways of apoptosis 
and necrosis are different. Therefore, dissimilarities can be identified in their metabolite 
profiles. Separating apoptotic and necrotic cells by methods such as flow cytometric cell 
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sorting may provide the opportunity to investigate specific MRS markers of each type of 
cell death.    
The use of other techniques such as mass spectrometry will provide additional information 
and identifying changes in metabolites not detected by NMR will help to reveal the altered 
pathways and to better understand the changes occurring in tumour cells. A comparison 
with studies of molecular quantities and gene expression of the tumours will further help to 
elucidate the molecular pathways. 
 
Investigations are required to identify the role of lipid droplets in stressed cells. Identifying 
the composition of the lipid bodies may be useful in achieving this purpose. Currently our 
team is extracting the lipid droplets from treated cells. The alteration in properties of the 
extracted lipid droplets in response to treatment are being studied by Nile red dye and 
fluorescence microscopy. In addition the nature of these lipid bodies will be investigated 
by MRS. 
 
Novel biomarkers such as glycine, glutamate, and taurine warrant further investigation. 
High levels of glycine, glutamate, taurine, and alanine were associated with high 
malignancy. Reduced levels of these metabolites in response to treatment, reveals their 
potential as markers of treatment. However, further work is required to examine the profile 
of these metabolites in response to treatment in in vivo settings. Currently further work is 
being carried out to further assess the potential of glycine as a biomarker in clinical 
settings.  
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The work carried out here and previous studies show the vast potential of MRS in 
treatment evaluation. MRS has also shown possible applications in tumour diagnosis and 
prognosis. However, further work and robust multi-centre trails are required to explore and 
validate the potential of MRS and increase its utility in clinical settings. 
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